Objective
The purpose of this study was to compare the transcriptome between the site of membrane rupture and the chorioamniotic membranes away from the site of rupture.
Study Design
The transcriptome of amnion and chorion (n = 20 each) from and distal to the site of rupture from women with spontaneous labor and vaginal delivery at term after spontaneous rupture of membranes was profiled with Illumina HumanHT-12 microarrays. Selected genes were validated with the use of quantitative reverse transcription–polymerase chain reaction.
Results
Six hundred seventy-seven genes were differentially expressed in the chorion between the rupture and nonrupture sites (false discovery rate <0.1; fold change >1.5). Quantitative reverse transcription–polymerase chain reaction confirmed the differential expression in 10 of 14 genes. Enriched biological processes included anatomic structure development, cell adhesion and signal transduction. Extracellular matrix–receptor interaction was the most impacted signaling pathway.
Conclusion
The transcriptome of fetal membranes after spontaneous rupture of membranes in term labor is characterized by region- and tissue-specific differential expression of genes that are involved in signature pathways, which include extracellular matrix–receptor interactions.
The common pathway of human parturition is characterized by anatomic, immunologic, and physiologic changes that occur in the mother and/or fetus in both term and preterm parturition. In normal pregnancy, the chorioamniotic membranes have important anatomic, biochemical, and antibacterial properties that serve to protect the fetus and pregnancy. The membranes (chorion and amnion) are intact during gestation and rupture without intervention close to the beginning of the second stage of labor.
The fetal membranes undergo complex physical and biochemical changes before the onset of labor at term. In patients at term without labor, the portion of the fetal membranes overlying the cervix contains characteristic histologic and biochemical changes and is thought to be the site at which eventual spontaneous rupture of membranes occurs. This area has been termed the “zone of altered morphology” (ZAM). Defined by histologic criteria, the membranes in the ZAM are thinner than in the membranes away from the ZAM. The features of the ZAM include an increase in the thickness of connective tissue of amnion and chorion and decreased thickness of the cytotrophoblast and decidual layers. Moreover, El Khwad et al demonstrated that the ZAM is a weak zone by using biophysical testing. Several mechanisms have been proposed to contribute to the weakening of the chorioamniotic membranes in the ZAM; these mechanisms include spontaneous separation of fetal membrane layers, the exposure of the membranes to cytokines and matrix-degrading enzymes that are present in the vagina and in amniotic fluid that are known to increase in normal pregnancy at term and in labor.
The use of high-dimensional biology technology has led to the identification of novel genes, proteins, and pathways that are involved in both term and preterm labor. Specifically, transcriptomics (the description of the entire set of genes that are transcribed by a particular tissue at a specific point in time) has been used to examine the differences in global gene expression profiles in intact fetal membranes of women at term with and without labor, women in term and preterm labor, and in pregnancies that are complicated by preterm labor with and without preterm prelabor rupture of membranes (PROM). Gene expression profiling of the chorioamniotic membranes in the context of spontaneous rupture of membranes (SROM) at the site of membrane rupture and away from the site of rupture has not been previously reported.
This study was undertaken to examine the differences in the transcriptome between the site of membrane rupture and a section of the intact chorioamniotic membranes away from the site of rupture in patients at term with spontaneous labor and to gain further insight into the biochemical changes that are associated with the phenomenon of membrane rupture.
Methods
Study group
A prospective study was designed to examine differential gene expression of the chorioamniotic membranes at the gross site of rupture and distant from the site of rupture; samples were obtained from women who were admitted with spontaneous labor at term with SROM (n = 30). The inclusion criteria were (1) gestational age of ≥37 weeks, (2) absence of medical or obstetric complications of pregnancy, (3) no antibiotic administration in labor for group beta streptococcus (GBS) prophylaxis, (4) absence of meconium staining of the amniotic fluid, (5) no prostaglandin administration, (6) no use of amnioinfusion, (7) vaginal birth, and (8) normal pregnancy outcome, including an infant who was of appropriate weight for gestational age without congenital anomalies and Apgar scores >7 at 1 and 5 minutes. All patients provided written informed consent for the collection and use of samples for research purposes under the protocols approved by the institutional review boards of Wayne State University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services.
Clinical definitions
Labor was defined as the presence of regular uterine contractions accompanied by progressive cervical dilation that led to delivery. SROM was defined as rupture of membranes in the presence of labor and confirmed with sterile speculum examination and a combination of pooling, ferning, and Nitrazine tests. An appropriate-for-gestational-age neonate was defined as a birthweight between the 10th and 90th percentile for the gestational age at birth. Histologic chorioamnionitis was diagnosed on the basis of the presence of inflammatory cells in the chorionic plate and/or chorioamniotic membranes. Acute funisitis was diagnosed by the presence of neutrophils in the wall of the umbilical vessels and/or Wharton’s jelly.
Collection of the fetal membranes
Fetal membranes were processed within 30 minutes of delivery. After the identification of the site of rupture, a linear piece of membrane that measured 1 × 4 cm and spanned the gross rupture site was dissected sharply ( Figure 1 ). Similarly, a 1 × 4 cm strip of reflected extraplacental membranes was removed at a site distal to the site of rupture that was approximately one-half the distance between the site of rupture and the placental disk. The amnion was separated from the chorion, and each tissue was flash-frozen with liquid nitrogen. This method yielded a set of 4 specimens from each patient: (1) amnion from the rupture site, (2) chorion from the rupture site, (3) amnion from the nonrupture site, and (4) chorion from the nonrupture site. In addition, a section of membranes from each patient was obtained for histologic examination with the use of hematoxylin-eosin–stained histologic sections. The cases with chorioamnionitis, funisitis, meconium-staining, or severe amnion degeneration were excluded from the study. The sets of specimens were collected prospectively until 30 total sets of fetal membranes were obtained that met all inclusion and histologic criteria. The RNA was extracted and stored at –70°C until it was assayed. The materials were housed at the bank of biologic specimens that was held at the Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Sampling sites of the fetal membranes
The image of the placenta demonstrates the representative sampling sites of the gross site of rupture ( yellow box ) and the site away from rupture ( white box ).
Nhan-Chang. The transcriptome of chorioamniotic membranes. Am J Obstet Gynecol 2010.
Microarray analysis and real-time quantitative polymerase chain reaction
For microarray analysis, complete sets of chorioamniotic membranes were used (n = 20 matched sets of amnion from the rupture site, chorion from the rupture site, amnion from the nonrupture site, and chorion from the nonrupture site from each patient). The Illumina HumanHT-12 expression microarray (version 3; Illumina, San Diego, CA) platform was used to measure the gene expression levels in each specimen, per manufacturer’s instructions. To verify the results from microarray, 14 genes were selected for quantitative polymerase chain reaction (qRT-PCR) assays in a subset of the original sample set (n =10) and in a new set of samples from patients at term with SROM (n = 10). The selection criteria for the new specimens were the same as those used to select patients for the microarray analysis, with the exception of 2 patients with mild intermittent asthma without asthma exacerbations or exposure to steroids during the index pregnancy. A detailed description of the method and analysis is available as supplementary material ( Supplement 1 ).
Statistical analyses
The raw gene expression data were normalized by a quantile normalization approach. A paired moderated t test was used to test for differential expression with a false discovery rate (FDR) threshold of 0.1 in conjunction with a threshold of 1.5 on the fold change to assign gene significance. Gene ontology analysis was performed with algorithms that were described previously. Pathway analysis was performed on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database with an overrepresentation analysis and the signaling pathway impact analysis. The signaling pathway impact analysis differs from the overrepresentation approaches by taking into account the gene-gene signaling interactions and the magnitude and direction of gene expression changes to determine significantly impacted pathways.
Differential expression between experimental regions from qRT-PCR data was performed with a paired t test on –ΔCt values. The Student t , Mann-Whitney U , and χ 2 tests were used to identify significant differences in patient demographics between women in the microarray and qRT-PCR groups. SPSS software (version 12.0; SPSS Inc, Chicago, IL) was used for statistical analysis of demographic data. A probability value of < .05 was considered statistically significant.
Results
Demographics
Table 1 displays the demographic characteristics of patients who were included in the microarray and qRT-PCR analyses.
TABLE 1
Patient demographics
| Demographic | Microarray (n = 20) | Quantitative reverse transcriptase–polymerase chain reaction (n = 10) | P value |
|---|---|---|---|
| Maternal age, y a | 24.5 (20.3–27.8) | 26 (20-30) | NS b |
| Gravidity, n a | 3 (2–4) | 2.5 (2–4.5) | NS c |
| Parity, n a | 1 (0–2) | 1 (0–2.8) | NS c |
| Maternal race, % | NS d | ||
| African American | 80 | 70 | |
| White | 10 | 10 | |
| Other | 10 | 20 | |
| Gestational age at delivery, wk a | 38.6 (38.2–40.1) | 39 (38.2–40.3) | NS b |
| Rupture of membranes-to-delivery interval, min a | 259 (104–624) | 121 (59–189) | NS c |
| Birthweight, g a | 3285 (3097–3360) | 3335 (3203–3409) | NS b |
NS , not significant.
Nhan-Chang. The transcriptome of chorioamniotic membranes. Am J Obstet Gynecol 2010.
a Values expressed as medians (interquartile range);
Results of the microarray analysis
Rupture site chorion vs nonrupture site chorion. Microarray analysis demonstrated 815 probes that corresponded with 677 unique genes that were expressed differentially in the chorion between the rupture and nonrupture sites (pFDR <0.1; fold change >1.5). A total of 453 genes had decreased expression, and 224 genes had increased expression in the rupture site, compared with the nonrupture site. A “volcano plot” shows the differential expression of all the annotated probes on the Illumina HumanHT-12 v3 array with the log (base 10) of the FDR-adjusted probability values (y-axis) plotted against the log (base 2) fold changes (x-axis) between the rupture site chorion and nonrupture site chorion ( Figure 2 ). A heat map that displays the hierarchical clustering of all samples and 200 probes whose expression had the largest variance across all amnion and chorion samples (both rupture and nonrupture sites) is shown in Figure 3 , A. Two main clusters are seen in the heat map that predominantly represent amnion from the rupture and nonrupture site in 1 cluster and chorion from the rupture and nonrupture site in the other cluster. A smaller cluster of mixed samples (both amnion and chorion and rupture vs nonrupture site specimens) is also seen in the heat map and represents specimens that did not fit into the 2 main clusters of specimens. Figure 3 , B, shows a hierarchical clustering of the 200 probes with the highest variance across only chorion specimens (both rupture and nonrupture site). A list of the top 100 differentially expressed genes between the rupture site chorion and nonrupture site chorion is presented in Table 2 ; the complete list of differentially expressed probes is available as supplementary material ( Supplement 2 ).
Transcriptomic analysis of chorion specimens
The volcano plot shows probability values of all probes in the microarray plotted against the fold changes. In this Figure, the log (base 10) of the false discovery rate–adjusted probability values are plotted against the log (base 2) ratio of fold changes between ruptured site chorion and nonruptured site chorion. On the Y-axis , values higher than the grey-line threshold represent significant probes with an adjusted probability value of < .1. On the X-axis , values outside the red lines represent fold-changes of ≥1.5 between ruptured site chorion and nonruptured site chorion. The 815 differentially expressed probes are labeled blue in the upper outer quadrants.
Nhan-Chang. The transcriptome of chorioamniotic membranes. Am J Obstet Gynecol 2010.
Heat maps of the clustering of genes
A , A heat map displays the hierarchical clustering of the 200 probes whose expression had the largest variance across all amnion and chorion specimens. The red and green colors in the heat map correspond with high and low gene expression, respectively. The labels at the top indicate individual patient samples and their membrane region designation. Two main clusters are seen that predominantly represent amnion from the rupture site and nonrupture site on the left and chorion from the rupture site and nonrupture site in the middle. A smaller cluster of mixed samples are on the right. B , A heat map displays the hierarchical clustering of the 200 probes whose expression had the largest variance across chorion specimens. Two separate cluster regions represent the rupture site on the right and nonrupture site on the left.
Nhan-Chang. The transcriptome of chorioamniotic membranes. Am J Obstet Gynecol 2010.
TABLE 2
List of the top 100 differentially expressed probes in chorion between the rupture site and nonruptured site
| Rank | Name | Entrez a | Symbol b | Fold change c | P value |
|---|---|---|---|---|---|
| 1 | Methyltransferase like 7A | 25840 | METTL7A | –1.9 | .000023 |
| 2 | Epoxide hydrolase 1, microsomal (xenobiotic) | 2052 | EPHX1 | –1.7 | .000048 |
| 3 | Arylacetamide deacetylase-like 2 | 344752 | AADACL2 | –4.5 | .000057 |
| 4 | KIT ligand | 4254 | KITLG | –1.6 | .000057 |
| 5 | Glutathione S-transferase alpha 4 | 2941 | GSTA4 | –1.6 | .000057 |
| 6 | Killer cell lectin-like receptor subfamily C, member 1 | 3821 | KLRC1 | –1.7 | .000069 |
| 7 | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | 6387 | CXCL12 | –1.7 | .000100 |
| 8 | Basic helix-loop-helix family, member e40 | 8553 | BHLHE40 | 1.6 | .000100 |
| 9 | Aldehyde oxidase 1 | 316 | AOX1 | –3.3 | .000100 |
| 10 | Meis homeobox 1 | 4211 | MEIS1 | –1.8 | .000100 |
| 11 | Complement factor I | 3426 | CFI | –1.7 | .000100 |
| 12 | Tetraspanin 7 | 7102 | TSPAN7 | –2.2 | .000110 |
| 13 | Phosphoglucomutase 5 | 5239 | PGM5 | –3.3 | .000120 |
| 14 | G protein-coupled receptor, family C, group 5, member A | 9052 | GPRC5A | 1.8 | .000140 |
| 15 | Arylacetamide deacetylase (esterase) | 13 | AADAC | –5.5 | .000140 |
| 16 | EGF-containing fibulin-like extracellular matrix protein 1 | 2202 | EFEMP1 | –2.2 | .000140 |
| 17 | Chromosome 12 open reading frame 48 | 55010 | C12orf48 | –1.8 | .000140 |
| 18 | B-cell CLL/lymphoma 2 | 596 | BCL2 | –2.3 | .000140 |
| 19 | Regulator of G-protein signaling 5 | 8490 | RGS5 | –2.0 | .000140 |
| 20 | BTB (POZ) domain containing 3 | 22903 | BTBD3 | –2.2 | .000140 |
| 21 | Phosphoribosyl pyrophosphate synthetase 2 | 5634 | PRPS2 | –1.7 | .000140 |
| 22 | Phosphoglucomutase 5 | 5239 | PGM5 | –3.3 | .000140 |
| 23 | Primary ciliary dyskinesia protein 1 | 200373 | hCG_17324 | –1.6 | .000150 |
| 24 | Killer cell lectin-like receptor subfamily C, member 1 | 3821 | KLRC1 | –2.1 | .000150 |
| 25 | Gtpase, IMAP family member 6 | 474344 | GIMAP6 | –2.2 | .000150 |
| 26 | Transmembrane 4 L 6 family member 18 | 116441 | TM4SF18 | –1.8 | .000150 |
| 27 | Interleukin 15 | 3600 | IL15 | –1.8 | .000160 |
| 28 | Lectin, galactoside-binding, soluble, 9 | 3965 | LGALS9 | –1.8 | .000170 |
| 29 | Plasticity related gene 1 | 9890 | LPPR4 | –1.6 | .000180 |
| 30 | Endo/exonuclease (5′-3′), endonuclease G-like | 9941 | EXOG | 2.0 | .000180 |
| 31 | CD34 molecule | 947 | CD34 | –3.3 | .000180 |
| 32 | MAP6 domain containing 1 | 79929 | MAP6D1 | 1.6 | .000180 |
| 33 | Calcitonin receptor-like | 10203 | CALCRL | –1.9 | .000180 |
| 34 | Cathepsin W | 1521 | CTSW | –2.2 | .000180 |
| 35 | Toll-like receptor 7 | 51284 | TLR7 | –1.5 | .000190 |
| 36 | G protein-coupled receptor 34 | 2857 | GPR34 | –1.8 | .000190 |
| 37 | Keratin 14 | 3861 | KRT14 | 3.0 | .000190 |
| 38 | Acetyl-coenzyme A acetyltransferase 1 | 38 | ACAT1 | –1.6 | .000190 |
| 39 | C-type lectin domain family 14, member A | 161198 | CLEC14A | –2.2 | .000190 |
| 40 | Similar to Complement C3 precursor | 653879 | LOC653879 | –2.6 | .000190 |
| 41 | Phosphoglucomutase 5 | 5239 | PGM5 | –2.2 | .000190 |
| 42 | Chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) | 6362 | CCL18 | –2.2 | .000190 |
| 43 | LIM domain binding 2 | 9079 | LDB2 | –2.1 | .000190 |
| 44 | GRB2-related adaptor protein | 10750 | GRAP | –1.9 | .000190 |
| 45 | B-cell CLL/lymphoma 2 | 596 | BCL2 | –1.9 | .000190 |
| 46 | Olfactomedin-like 1 | 283298 | OLFML1 | –1.6 | .000190 |
| 47 | CHK2 checkpoint homolog (S. Pombe) | 11200 | CHEK2 | –1.6 | .000190 |
| 48 | Gtpase, IMAP family member 7 | 168537 | GIMAP7 | –2.4 | .000190 |
| 49 | Chromosome 5 open reading frame 4 | 10826 | C5orf4 | –1.9 | .000190 |
| 50 | Sterile alpha motif domain containing 3 | 154075 | SAMD3 | –1.6 | .000190 |
| 51 | Src kinase associated phosphoprotein 1 | 8631 | SKAP1 | –1.7 | .000190 |
| 52 | Tetraspanin 7 | 7102 | TSPAN7 | –2.5 | .000190 |
| 53 | Teashirt zinc finger homeobox 2 | 128553 | TSHZ2 | –2.1 | .000190 |
| 54 | Transcobalamin II; macrocytic anemia | 6948 | TCN2 | –1.9 | .000190 |
| 55 | Purinergic receptor P2Y, G-protein coupled, 14 | 9934 | P2RY14 | –2.7 | .000190 |
| 56 | Family with sequence similarity 150, member B | 285016 | FAM150B | –3.1 | .000200 |
| 57 | Carboxypeptidase B1 (tissue) | 1360 | CPB1 | –2.8 | .000200 |
| 58 | Regulator of G-protein signaling 22 | 26166 | RGS22 | –2.8 | .000200 |
| 59 | Uracil-DNA glycosylase | 7374 | UNG | –1.6 | .000210 |
| 60 | Phospholipid scramblase 4 | 57088 | PLSCR4 | –1.7 | .000210 |
| 61 | Dynein, cytoplasmic 2, light intermediate chain 1 | 51626 | DYNC2LI1 | –1.6 | .000220 |
| 62 | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | 6387 | CXCL12 | –1.9 | .000220 |
| 63 | Uridine phosphorylase 1 | 7378 | UPP1 | 1.6 | .000220 |
| 64 | Pyruvate dehydrogenase kinase, isozyme 4 | 5166 | PDK4 | –2.2 | .000230 |
| 65 | Nuclear factor I/B | 4781 | NFIB | –2.0 | .000230 |
| 66 | Regulator of G-protein signaling 5 | 8490 | RGS5 | –1.9 | .000250 |
| 67 | Chromosome 21 open reading frame 34 | 388815 | C21orf34 | –1.8 | .000250 |
| 68 | Pannexin 1 | 24145 | PANX1 | 1.6 | .000250 |
| 69 | Acetyl-coenzyme A carboxylase beta | 32 | ACACB | –1.6 | .000270 |
| 70 | CHK2 checkpoint homolog (S. Pombe) | 11200 | CHEK2 | –1.6 | .000280 |
| 71 | Family with sequence similarity 5, member B | 57795 | FAM5B | –2.0 | .000280 |
| 72 | Integral membrane protein 2A | 9452 | ITM2A | –2.3 | .000280 |
| 73 | Chemokine (C-C motif) ligand 15 | 6359 | CCL15 | –2.2 | .000290 |
| 74 | ATP-binding cassette, sub-family A (ABC1), member 8 | 10351 | ABCA8 | –2.2 | .000290 |
| 75 | Lectin, galactoside-binding, soluble, 9 | 3965 | LGALS9 | –2.0 | .000290 |
| 76 | Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 5295 | PIK3R1 | –1.7 | .000290 |
| 77 | Gap junction protein, alpha 4, 37 kd | 2701 | GJA4 | –1.6 | .000290 |
| 78 | Sorting nexin family member 21 | 90203 | SNX21 | –1.6 | .000300 |
| 79 | Phosphoribosyl pyrophosphate synthetase 2 | 5634 | PRPS2 | –1.5 | .000300 |
| 80 | LRRN4 C-terminal like | 221091 | LRRN4CL | –1.8 | .000310 |
| 81 | Transmembrane protein 27 | 57393 | TMEM27 | –2.0 | .000340 |
| 82 | CD34 molecule | 947 | CD34 | –3.2 | .000340 |
| 83 | Von Willebrand factor | 7450 | VWF | –4.3 | .000350 |
| 84 | Major histocompatibility complex, class II, DO alpha | 3111 | HLA-DOA | –1.9 | .000360 |
| 85 | Granzyme A (granzyme 1) | 3001 | GZMA | –2.9 | .000380 |
| 86 | Transforming growth factor, beta-induced, 68 kd | 7045 | TGFBI | 1.6 | .000390 |
| 87 | Nuclear factor I/B | 4781 | NFIB | –2.0 | .000390 |
| 88 | Galactosidase, beta 1-like 2 | 89944 | GLB1L2 | –2.3 | .000390 |
| 89 | Endoplasmic reticulum metallopeptidase 1 | 79956 | ERMP1 | –1.5 | .000400 |
| 90 | Serum deprivation response (phosphatidylserine binding protein) | 8436 | SDPR | –2.2 | .000410 |
| 91 | ABI family, member 3 | 51225 | ABI3 | –1.6 | .000420 |
| 92 | Sterol-C4-methyl oxidase-like | 6307 | SC4MOL | 1.6 | .000430 |
| 93 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 | 8140 | SLC7A5 | 1.9 | .000430 |
| 94 | Src homology 2 domain containing E | 126669 | SHE | –1.5 | .000440 |
| 95 | Similar to Complement C3 precursor | 653879 | LOC653879 | –2.2 | .000440 |
| 96 | Ras homolog gene family, member J | 57381 | RHOJ | –1.9 | .000440 |
| 97 | Membrane-spanning 4-domains, subfamily A, member 4 | 51338 | MS4A4A | –1.7 | .000440 |
| 98 | Hypothetic protein LOC100133666 | 100133666 | LOC100133666 | –1.6 | .000440 |
| 99 | Frizzled homolog 8 ( Drosophila ) | 8325 | FZD8 | 1.7 | .000440 |
| 100 | Osteoglycin | 4969 | OGN | –2.7 | .000440 |
ABI , Abelson-interactor; ATP , adenosine triphospate; BTB , Broad-complex, Tramtrack and Bric-abrac; CD34 , cluster of differentiation 34; CHK2 , checkpoint kinase 2; CLL , chronic lymphocytic leukemia; EGF , epidermal growth factor; GRB2 , growth factor receptor-bound protein 2; IMAP , immunity-associated protein; KIT , c-Kit; LRRN4 , leucine rich repeat neuronal 4; MAP6 , micortubule-associated protein 6; POZ , poxvirus and zinc finger.
Nhan-Chang. The transcriptome of chorioamniotic membranes. Am J Obstet Gynecol 2010.
b Symbol was taken from the gene database and corresponds to official Human Genome Organization Gene Nomenclature Committee symbols;
c fold change (the number of times the average expression level in the ruptured sites is different from the average expression level in the nonruptured sites) refers to probe expression change in ruptured chorion relative to nonruptured chorion; positive values (no sign) indicate increased expression, and negative values (minus sign) indicate decreased expression.
SUPPLEMENT 2
List of all probes that were expressed differentially in chorion between rupture site and nonrupture site
| Rank | Entrez | Name | Symbol | Fold change | Adjusted P value |
|---|---|---|---|---|---|
| 1 | 25840 | Methyltransferase like 7A | METTL7A | –1.9 | .000023 |
| 2 | 2052 | Epoxide hydrolase 1, microsomal (xenobiotic) | EPHX1 | –1.7 | .000048 |
| 3 | 344752 | Arylacetamide deacetylase-like 2 | AADACL2 | –4.5 | .000057 |
| 4 | 4254 | KIT ligand | KITLG | –1.6 | .000057 |
| 5 | 2941 | Glutathione S-transferase alpha 4 | GSTA4 | –1.6 | .000057 |
| 6 | 3821 | Killer cell lectin-like receptor subfamily C, member 1 | KLRC1 | –1.7 | .000069 |
| 7 | 6387 | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | CXCL12 | –1.7 | .0001 |
| 8 | 8553 | Basic helix-loop-helix family, member e40 | BHLHE40 | 1.6 | .0001 |
| 9 | 316 | Aldehyde oxidase 1 | AOX1 | –3.3 | .0001 |
| 10 | 4211 | Meis homeobox 1 | MEIS1 | –1.8 | .0001 |
| 11 | 3426 | Complement factor I | CFI | –1.7 | .0001 |
| 12 | 7102 | Tetraspanin 7 | TSPAN7 | –2.2 | .00011 |
| 13 | 5239 | Phosphoglucomutase 5 | PGM5 | –3.3 | .00012 |
| 14 | 9052 | G protein-coupled receptor, family C, group 5, member A | GPRC5A | 1.8 | .00014 |
| 15 | 13 | Arylacetamide deacetylase (esterase) | AADAC | –5.5 | .00014 |
| 16 | 2202 | EGF-containing fibulin-like extracellular matrix protein 1 | EFEMP1 | –2.2 | .00014 |
| 17 | 55010 | Chromosome 12 open reading frame 48 | C12orf48 | –1.8 | .00014 |
| 18 | 596 | B-cell CLL/lymphoma 2 | BCL2 | –2.3 | .00014 |
| 19 | 8490 | Regulator of G-protein signaling 5 | RGS5 | –2 | .00014 |
| 20 | 22903 | BTB (POZ) domain containing 3 | BTBD3 | –2.2 | .00014 |
| 21 | 5634 | Phosphoribosyl pyrophosphate synthetase 2 | PRPS2 | –1.7 | .00014 |
| 22 | 5239 | Phosphoglucomutase 5 | PGM5 | –3.3 | .00014 |
| 23 | 200373 | Primary ciliary dyskinesia protein 1 | hCG_17324 | –1.6 | .00015 |
| 24 | 3821 | Killer cell lectin-like receptor subfamily C, member 1 | KLRC1 | –2.1 | .00015 |
| 25 | 474344 | Gtpase, IMAP family member 6 | GIMAP6 | –2.2 | .00015 |
| 26 | 116441 | Transmembrane 4 L six family member 18 | TM4SF18 | –1.8 | .00015 |
| 27 | 3600 | Interleukin 15 | IL15 | –1.8 | .00016 |
| 28 | 3965 | Lectin, galactoside-binding, soluble, 9 | LGALS9 | –1.8 | .00017 |
| 29 | 9890 | Plasticity related gene 1 | LPPR4 | –1.6 | .00018 |
| 30 | 9941 | Endo/exonuclease (5′-3′), endonuclease G-like | EXOG | 2 | .00018 |
| 31 | 947 | CD34 molecule | CD34 | –3.3 | .00018 |
| 32 | 79929 | MAP6 domain containing 1 | MAP6D1 | 1.6 | .00018 |
| 33 | 10203 | Calcitonin receptor-like | CALCRL | –1.9 | .00018 |
| 34 | 1521 | Cathepsin W | CTSW | –2.2 | .00018 |
| 35 | 51284 | Toll-like receptor 7 | TLR7 | –1.5 | .00019 |
| 36 | 2857 | G protein-coupled receptor 34 | GPR34 | –1.8 | .00019 |
| 37 | 3861 | Keratin 14 | KRT14 | 3 | .00019 |
| 38 | 38 | Acetyl-coenzyme A acetyltransferase 1 | ACAT1 | –1.6 | .00019 |
| 39 | 161198 | C-type lectin domain family 14, member A | CLEC14A | –2.2 | .00019 |
| 40 | 653879 | Similar to complement C3 precursor | LOC653879 | –2.6 | .00019 |
| 41 | 5239 | Phosphoglucomutase 5 | PGM5 | –2.2 | .00019 |
| 42 | 6362 | Chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) | CCL18 | –2.2 | .00019 |
| 43 | 9079 | LIM domain binding 2 | LDB2 | –2.1 | .00019 |
| 44 | 10750 | GRB2-related adaptor protein | GRAP | –1.9 | .00019 |
| 45 | 596 | B-cell CLL/lymphoma 2 | BCL2 | –1.9 | .00019 |
| 46 | 283298 | Olfactomedin-like 1 | OLFML1 | –1.6 | .00019 |
| 47 | 11200 | CHK2 checkpoint homolog (S. Pombe) | CHEK2 | –1.6 | .00019 |
| 48 | 168537 | Gtpase, IMAP family member 7 | GIMAP7 | –2.4 | .00019 |
| 49 | 10826 | Chromosome 5 open reading frame 4 | C5orf4 | –1.9 | .00019 |
| 50 | 154075 | Sterile alpha motif domain containing 3 | SAMD3 | –1.6 | .00019 |
| 51 | 8631 | Src kinase associated phosphoprotein 1 | SKAP1 | –1.7 | .00019 |
| 52 | 7102 | Tetraspanin 7 | TSPAN7 | –2.5 | .00019 |
| 53 | 128553 | Teashirt zinc finger homeobox 2 | TSHZ2 | –2.1 | .00019 |
| 54 | 6948 | Transcobalamin II; macrocytic anemia | TCN2 | –1.9 | .00019 |
| 55 | 9934 | Purinergic receptor P2Y, G-protein coupled, 14 | P2RY14 | –2.7 | .00019 |
| 56 | 285016 | Family with sequence similarity 150, member B | FAM150B | –3.1 | .0002 |
| 57 | 1360 | Carboxypeptidase B1 (tissue) | CPB1 | –2.8 | .0002 |
| 58 | 26166 | Regulator of G-protein signaling 22 | RGS22 | –2.8 | .0002 |
| 59 | 7374 | Uracil-DNA glycosylase | UNG | –1.6 | .00021 |
| 60 | 57088 | Phospholipid scramblase 4 | PLSCR4 | –1.7 | .00021 |
| 61 | 51626 | Dynein, cytoplasmic 2, light intermediate chain 1 | DYNC2LI1 | –1.6 | .00022 |
| 62 | 6387 | Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) | CXCL12 | –1.9 | .00022 |
| 63 | 7378 | Uridine phosphorylase 1 | UPP1 | 1.6 | .00022 |
| 64 | 5166 | Pyruvate dehydrogenase kinase, isozyme 4 | PDK4 | –2.2 | .00023 |
| 65 | 4781 | Nuclear factor I/B | NFIB | –2 | .00023 |
| 66 | 8490 | Regulator of G-protein signaling 5 | RGS5 | –1.9 | .00025 |
| 67 | 388815 | Chromosome 21 open reading frame 34 | C21orf34 | –1.8 | .00025 |
| 68 | 24145 | Pannexin 1 | PANX1 | 1.6 | .00025 |
| 69 | 32 | Acetyl-Coenzyme A carboxylase beta | ACACB | –1.6 | .00027 |
| 70 | 11200 | CHK2 checkpoint homolog (S. Pombe) | CHEK2 | –1.6 | .00028 |
| 71 | 57795 | Family with sequence similarity 5, member B | FAM5B | –2 | .00028 |
| 72 | 9452 | Integral membrane protein 2A | ITM2A | –2.3 | .00028 |
| 73 | 6359 | Chemokine (C-C motif) ligand 15 | CCL15 | –2.2 | .00029 |
| 74 | 10351 | ATP-binding cassette, sub-family A (ABC1), member 8 | ABCA8 | –2.2 | .00029 |
| 75 | 3965 | Lectin, galactoside-binding, soluble, 9 | LGALS9 | –2 | .00029 |
| 76 | 5295 | Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | PIK3R1 | –1.7 | .00029 |
| 77 | 2701 | Gap junction protein, alpha 4, 37 kd | GJA4 | –1.6 | .00029 |
| 78 | 90203 | Sorting nexin family member 21 | SNX21 | –1.6 | .0003 |
| 79 | 5634 | Phosphoribosyl pyrophosphate synthetase 2 | PRPS2 | –1.5 | .0003 |
| 80 | 221091 | LRRN4 C-terminal like | LRRN4CL | –1.8 | .00031 |
| 81 | 57393 | Transmembrane protein 27 | TMEM27 | –2 | .00034 |
| 82 | 947 | CD34 molecule | CD34 | –3.2 | .00034 |
| 83 | 7450 | Von Willebrand factor | VWF | –4.3 | .00035 |
| 84 | 3111 | Major histocompatibility complex, class II, DO alpha | HLA-DOA | –1.9 | .00036 |
| 85 | 3001 | Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | GZMA | –2.9 | .00038 |
| 86 | 7045 | Transforming growth factor, beta-induced, 68 kd | TGFBI | 1.6 | .00039 |
| 87 | 4781 | Nuclear factor I/B | NFIB | –2 | .00039 |
| 88 | 89944 | Galactosidase, beta 1-like 2 | GLB1L2 | –2.3 | .00039 |
| 89 | 79956 | Endoplasmic reticulum metallopeptidase 1 | ERMP1 | –1.5 | .0004 |
| 90 | 8436 | Serum deprivation response (phosphatidylserine binding protein) | SDPR | –2.2 | .00041 |
| 91 | 51225 | ABI family, member 3 | ABI3 | –1.6 | .00042 |
| 92 | 6307 | Sterol-C4-methyl oxidase-like | SC4MOL | 1.6 | .00043 |
| 93 | 8140 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 | SLC7A5 | 1.9 | .00043 |
| 94 | 126669 | Src homology 2 domain containing E | SHE | –1.5 | .00044 |
| 95 | 653879 | Similar to Complement C3 precursor | LOC653879 | –2.2 | .00044 |
| 96 | 57381 | Ras homolog gene family, member J | RHOJ | –1.9 | .00044 |
| 97 | 51338 | Membrane-spanning 4-domains, subfamily A, member 4 | MS4A4A | –1.7 | .00044 |
| 98 | 100133666 | Hypothetical protein LOC100133666 | LOC100133666 | –1.6 | .00044 |
| 99 | 8325 | Frizzled homolog 8 ( Drosophila ) | FZD8 | 1.7 | .00044 |
| 100 | 4969 | Osteoglycin | OGN | –2.7 | .00044 |
| 101 | 151647 | Family with sequence similarity 19 (chemokine (C-C motif)-like), member A4 | FAM19A4 | –1.6 | .00044 |
| 102 | 3898 | Ladinin 1 | LAD1 | 2.3 | .00045 |
| 103 | 4675 | Nucleosome assembly protein 1-like 3 | NAP1L3 | –2.2 | .00046 |
| 104 | 7122 | Claudin 5 | CLDN5 | –3.1 | .00046 |
| 105 | 2199 | Fibulin 2 | FBLN2 | –1.7 | .00048 |
| 106 | 2028 | Glutamyl aminopeptidase (aminopeptidase A) | ENPEP | –1.6 | .00048 |
| 107 | 79630 | Chromosome 1 open reading frame 54 | C1orf54 | –1.6 | .00048 |
| 108 | 5168 | Ectonucleotide pyrophosphatase/phosphodiesterase 2 | ENPP2 | –3.7 | .00049 |
| 109 | 22903 | BTB (POZ) domain containing 3 | BTBD3 | –2 | .00049 |
| 110 | 2217 | Fc fragment of igg, receptor, transporter, alpha | FCGRT | –1.7 | .0005 |
| 111 | 285 | Angiopoietin 2 | ANGPT2 | –2.6 | .0005 |
| 112 | 7035 | Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) | TFPI | –1.7 | .0005 |
| 113 | 914 | CD2 molecule | CD2 | –2.3 | .0005 |
| 114 | 116441 | Transmembrane 4 L six family member 18 | TM4SF18 | –1.5 | .0005 |
| 115 | 151306 | G protein-coupled bile acid receptor 1 | GPBAR1 | –3.1 | .0005 |
| 116 | 54345 | SRY (sex determining region Y)-box 18 | SOX18 | –2.1 | .00052 |
| 117 | 1113 | Chromogranin A (parathyroid secretory protein 1) | CHGA | –1.7 | .00052 |
| 118 | 57419 | Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 | SLC24A3 | –2.1 | .00052 |
| 119 | 83643 | Coiled-coil domain containing 3 | CCDC3 | –1.7 | .00052 |
| 120 | 10461 | C-mer proto-oncogene tyrosine kinase | MERTK | –1.8 | .00053 |
| 121 | 4192 | Midkine (neurite growth-promoting factor 2) | MDK | –1.6 | .00055 |
| 122 | 144195 | Solute carrier family 2 (facilitated glucose transporter), member 14 | SLC2A14 | 1.9 | .00056 |
| 123 | 984 | Cell division cycle 2-like 1 (PITSLRE proteins) | CDC2L1 | 1.5 | .00056 |
| 124 | 54976 | Chromosome 20 open reading frame 27 | C20orf27 | –1.6 | .00059 |
| 125 | 10659 | CUG triplet repeat, RNA binding protein 2 | CUGBP2 | –1.6 | .00063 |
| 126 | 5168 | Ectonucleotide pyrophosphatase/phosphodiesterase 2 | ENPP2 | –3.8 | .00063 |
| 127 | 4958 | Osteomodulin | OMD | –3 | .00064 |
| 128 | 64231 | Membrane-spanning 4-domains, subfamily A, member 6A | MS4A6A | –2.3 | .00064 |
| 129 | 5334 | Phospholipase C-like 1 | PLCL1 | –1.8 | .00064 |
| 130 | 25878 | Matrix-remodelling associated 5 | MXRA5 | 2.6 | .00066 |
| 131 | 257101 | Zinc finger protein 683 | ZNF683 | –1.7 | .00067 |
| 132 | 23102 | TBC1 domain family, member 2B | TBC1D2B | –1.6 | .00067 |
| 133 | 2122 | Ecotropic viral integration site 1 | EVI1 | –1.6 | .00068 |
| 134 | 10045 | SH2 domain containing 3A | SH2D3A | 1.6 | .00068 |
| 135 | 2786 | Guanine nucleotide binding protein (G protein), gamma 4 | GNG4 | –2.3 | .00068 |
| 136 | 2359 | Formyl peptide receptor 3 | FPR3 | –2.1 | .00068 |
| 137 | 6414 | Selenoprotein P, plasma, 1 | SEPP1 | –2.5 | .00068 |
| 138 | 2202 | EGF-containing fibulin-like extracellular matrix protein 1 | EFEMP1 | –2 | .00068 |
| 139 | 256691 | MAM domain containing 2 | MAMDC2 | –2.4 | .00068 |
| 140 | 81788 | NUAK family, SNF1-like kinase, 2 | NUAK2 | 1.9 | .00068 |
| 141 | 7139 | Troponin T type 2 (cardiac) | TNNT2 | 1.5 | .00069 |
| 142 | 3909 | Laminin, alpha 3 | LAMA3 | 1.8 | .00069 |
| 143 | 27075 | Tetraspanin 13 | TSPAN13 | 1.7 | .00072 |
| 144 | 956 | Ectonucleoside triphosphate diphosphohydrolase 3 | ENTPD3 | –2.2 | .00073 |
| 145 | 837 | Caspase 4, apoptosis-related cysteine peptidase | CASP4 | –1.7 | .00075 |
| 146 | 654346 | Lectin, galactoside-binding, soluble, 9C | LGALS9C | –1.6 | .00077 |
| 147 | 122786 | FERM domain containing 6 | FRMD6 | 1.8 | .00078 |
| 148 | 60489 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | APOBEC3G | –1.5 | .00078 |
| 149 | 54453 | Ras and Rab interactor 2 | RIN2 | –1.5 | .00078 |
| 150 | 10276 | Neuroepithelial cell transforming 1 | NET1 | 1.9 | .00078 |
| 151 | 6366 | Chemokine (C-C motif) ligand 21 | CCL21 | –3.9 | .00078 |
| 152 | 7159 | Tumor protein p53 binding protein, 2 | TP53BP2 | 1.6 | .00078 |
| 153 | 10628 | Thioredoxin interacting protein | TXNIP | –2.1 | .00078 |
| 154 | 10578 | Granulysin | GNLY | –4.4 | .00078 |
| 155 | 255783 | Hypothetic protein LOC255783 | LOC255783 | –1.6 | .00078 |
| 156 | 7704 | Zinc finger and BTB domain containing 16 | ZBTB16 | –1.6 | .00078 |
| 157 | 434 | Agouti signaling protein, nonagouti homolog (mouse) | ASIP | –1.7 | .00078 |
| 158 | 5352 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | PLOD2 | 1.8 | .00078 |
| 159 | 7351 | Uncoupling protein 2 (mitochondrial, proton carrier) | UCP2 | –1.9 | .00078 |
| 160 | 64066 | Matrix metallopeptidase 27 | MMP27 | –1.5 | .00078 |
| 161 | 6461 | Src homology 2 domain containing adaptor protein B | SHB | 1.5 | .00082 |
| 162 | 2018 | Empty spiracles homeobox 2 | EMX2 | –1.7 | .00082 |
| 163 | 3910 | Laminin, alpha 4 | LAMA4 | –1.9 | .00083 |
| 164 | 5352 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | PLOD2 | 1.9 | .00083 |
| 165 | 9892 | Synaptosomal-associated protein, 91 kd homolog (mouse) | SNAP91 | –3 | .00083 |
| 166 | 6955 | T cell receptor alpha locus | TRA@ | –1.8 | .00083 |
| 167 | 1545 | Cytochrome P450, family 1, subfamily B, polypeptide 1 | CYP1B1 | –2.1 | .00083 |
| 168 | 8322 | Frizzled homolog 4 ( Drosophila ) | FZD4 | –1.9 | .00083 |
| 169 | 4489 | Metallothionein 1A | MT1A | 1.6 | .00083 |
| 170 | 1311 | Cartilage oligomeric matrix protein | COMP | 3.6 | .00083 |
| 171 | 55340 | Gtpase, IMAP family member 5 | GIMAP5 | –1.8 | .00087 |
| 172 | 10578 | Granulysin | GNLY | –3.9 | .00087 |
| 173 | 145781 | GRINL1A complex locus | GCOM1 | –1.5 | .00087 |
| 174 | 57460 | Protein phosphatase 1H (PP2C domain containing) | PPM1H | –2 | .00087 |
| 175 | 1471 | Cystatin C | CST3 | –1.5 | .00088 |
| 176 | 51129 | Angiopoietin-like 4 | ANGPTL4 | 2.4 | .00088 |
| 177 | 54456 | Mov10l1, Moloney leukemia virus 10-like 1, homolog (mouse) | MOV10L1 | –1.5 | .0009 |
| 178 | 79614 | Chromosome 5 open reading frame 23 | C5orf23 | –1.9 | .00091 |
| 179 | 91461 | Protein kinase-like protein sgk493 | SGK493 | –1.7 | .00091 |
| 180 | 151647 | Family with sequence similarity 19 (chemokine (C-C motif)-like), member A4 | FAM19A4 | –1.6 | .00094 |
| 181 | 3485 | Insulin-like growth factor binding protein 2, 36 kd | IGFBP2 | –3 | .00099 |
| 182 | 6988 | T-cell leukemia translocation altered gene | TCTA | –1.6 | .001 |
| 183 | 57381 | Ras homolog gene family, member J | RHOJ | –1.6 | .001 |
| 184 | 57555 | Neuroligin 2 | NLGN2 | –1.6 | .001 |
| 185 | 6764 | Suppression of tumorigenicity 5 | ST5 | 1.6 | .001 |
| 186 | 8804 | Cellular repressor of E1A-stimulated genes 1 | CREG1 | –1.5 | .001 |
| 187 | 9781 | Ring finger protein 144A | RNF144A | –1.5 | .001 |
| 188 | 4969 | Osteoglycin | OGN | –3.1 | .001 |
| 189 | 5090 | Pre-B-cell leukemia homeobox 3 | PBX3 | –1.6 | .001 |
| 190 | 285195 | Solute carrier family 9 (sodium/hydrogen exchanger), member 9 | SLC9A9 | –1.5 | .001 |
| 191 | 23166 | Stabilin 1 | STAB1 | –1.7 | .001 |
| 192 | 7704 | Zinc finger and BTB domain containing 16 | ZBTB16 | –1.6 | .0011 |
| 193 | 4502 | Metallothionein 2A | MT2A | 1.6 | .0011 |
| 194 | 2810 | Stratifin | SFN | 2.6 | .0011 |
| 195 | 3600 | Interleukin 15 | IL15 | –2.2 | .0011 |
| 196 | 3804 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 | KIR2DL3 | –2.3 | .0011 |
| 197 | 440871 | Similar to hcg2043206 | LOC440871 | –1.6 | .0011 |
| 198 | 5950 | Retinol binding protein 4, plasma | RBP4 | –2.2 | .0011 |
| 199 | 205 | Adenylate kinase 3-like 1 | AK3L1 | 1.5 | .0011 |
| 200 | 3125 | Major histocompatibility complex, class II, DR beta 3 | HLA-DRB3 | –1.9 | .0011 |
| 201 | 347735 | Serine incorporator 2 | SERINC2 | 1.7 | .0011 |
| 202 | 4015 | Lysyl oxidase | LOX | 2.3 | .0011 |
| 203 | 8788 | Delta-like 1 homolog ( Drosophila ) | DLK1 | 2.1 | .0012 |
| 204 | 11119 | Butyrophilin, subfamily 3, member A1 | BTN3A1 | –1.6 | .0012 |
| 205 | 6713 | Squalene epoxidase | SQLE | 1.7 | .0012 |
| 206 | 55959 | Sulfatase 2 | SULF2 | –2.1 | .0012 |
| 207 | 8644 | Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) | AKR1C3 | –1.7 | .0012 |
| 208 | 3872 | Keratin 17 | KRT17 | 2.6 | .0012 |
| 209 | 3003 | Granzyme K (granzyme 3; tryptase II) | GZMK | –1.7 | .0012 |
| 210 | 85016 | Chromosome 11 open reading frame 70 | C11orf70 | –1.5 | .0012 |
| 211 | 10894 | Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1 | –2.7 | .0012 |
| 212 | 11118 | Butyrophilin, subfamily 3, member A2 | BTN3A2 | –1.6 | .0012 |
| 213 | 54510 | Protocadherin 18 | PCDH18 | –1.7 | .0012 |
| 214 | 89795 | Neuron navigator 3 | NAV3 | –1.8 | .0012 |
| 215 | 2202 | EGF-containing fibulin-like extracellular matrix protein 1 | EFEMP1 | –2 | .0012 |
| 216 | 151306 | G protein-coupled bile acid receptor 1 | GPBAR1 | –3.5 | .0012 |
| 217 | 64231 | Membrane-spanning 4-domains, subfamily A, member 6A | MS4A6A | –2.3 | .0012 |
| 218 | 90293 | Kelch-like 13 ( Drosophila ) | KLHL13 | –2 | .0013 |
| 219 | 6307 | Sterol-C4-methyl oxidase-like | SC4MOL | 1.6 | .0013 |
| 220 | 91851 | Chordin-like 1 | CHRDL1 | –2.2 | .0013 |
| 221 | 6713 | Squalene epoxidase | SQLE | 1.8 | .0013 |
| 222 | 222584 | Family with sequence similarity 83, member B | FAM83B | 1.6 | .0013 |
| 223 | 1580 | Cytochrome P450, family 4, subfamily B, polypeptide 1 | CYP4B1 | –2.5 | .0013 |
| 224 | 51365 | Phospholipase A1 member A | PLA1A | –1.8 | .0013 |
| 225 | 10742 | Retinoic acid induced 2 | RAI2 | –2 | .0013 |
| 226 | 91851 | Chordin-like 1 | CHRDL1 | –2.2 | .0013 |
| 227 | 30061 | Solute carrier family 40 (iron-regulated transporter), member 1 | SLC40A1 | –1.9 | .0013 |
| 228 | 956 | Ectonucleoside triphosphate diphosphohydrolase 3 | ENTPD3 | –2 | .0013 |
| 229 | 1301 | Collagen, type XI, alpha 1 | COL11A1 | 2.6 | .0013 |
| 230 | 147040 | Potassium channel tetramerisation domain containing 11 | KCTD11 | 1.6 | .0013 |
| 231 | 1580 | Cytochrome P450, family 4, subfamily B, polypeptide 1 | CYP4B1 | –2.4 | .0014 |
| 232 | 2534 | FYN oncogene related to SRC, FGR, YES | FYN | –1.6 | .0014 |
| 233 | 78989 | Collectin sub-family member 11 | COLEC11 | –1.9 | .0014 |
| 234 | 3820 | Killer cell lectin-like receptor subfamily B, member 1 | KLRB1 | –2.3 | .0014 |
| 235 | 219654 | Zinc finger, CCHC domain containing 24 | ZCCHC24 | –1.8 | .0014 |
| 236 | 347733 | Tubulin, beta 2B | TUBB2B | 2 | .0014 |
| 237 | 6480 | ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 | ST6GAL1 | –1.6 | .0014 |
| 238 | 3910 | Laminin, alpha 4 | LAMA4 | –2.5 | .0014 |
| 239 | 6925 | Transcription factor 4 | TCF4 | –1.7 | .0014 |
| 240 | 1675 | Complement factor D (adipsin) | CFD | –2.8 | .0014 |
| 241 | 924 | CD7 molecule | CD7 | –1.9 | .0014 |
| 242 | 9071 | Claudin 10 | CLDN10 | –1.7 | .0014 |
| 243 | 5783 | Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) | PTPN13 | –2 | .0015 |
| 244 | 51330 | Tumor necrosis factor receptor superfamily, member 12A | TNFRSF12A | 1.7 | .0015 |
| 245 | 915 | CD3d molecule, delta (CD3-TCR complex) | CD3D | –2 | .0015 |
| 246 | 2534 | FYN oncogene related to SRC, FGR, YES | FYN | –1.5 | .0015 |
| 247 | 7035 | Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) | TFPI | –1.6 | .0015 |
| 248 | 5649 | Reelin | RELN | –1.9 | .0015 |
| 249 | 89778 | Serpin peptidase inhibitor, clade B (ovalbumin), member 11 (gene/pseudogene) | SERPINB11 | –1.5 | .0015 |
| 250 | 283316 | CD163 molecule-like 1 | CD163L1 | –1.8 | .0015 |
| 251 | 8622 | Phosphodiesterase 8B | PDE8B | –2.4 | .0015 |
| 252 | 925 | CD8a molecule | CD8A | –1.8 | .0016 |
| 253 | 5551 | Perforin 1 (pore forming protein) | PRF1 | –2.1 | .0016 |
| 254 | 5352 | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 | PLOD2 | 2 | .0016 |
| 255 | 55930 | Myosin VC | MYO5C | –1.6 | .0016 |
| 256 | 1879 | Early B-cell factor 1 | EBF1 | –1.8 | .0016 |
| 257 | 652891 | Similar to Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta) (VAC-beta) | LOC652891 | 2 | .0016 |
| 258 | 8788 | Delta-like 1 homolog ( Drosophila ) | DLK1 | 2.6 | .0017 |
| 259 | 6853 | Synapsin I | SYN1 | 1.8 | .0017 |
| 260 | 5783 | Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) | PTPN13 | –1.8 | .0017 |
| 261 | 55506 | H2A histone family, member Y2 | H2AFY2 | –1.7 | .0017 |
| 262 | 244 | Annexin A8-like 2 | ANXA8L2 | 1.9 | .0018 |
| 263 | 79901 | Cytochrome b reductase 1 | CYBRD1 | –1.5 | .0018 |
| 264 | 1003 | Cadherin 5, type 2 (vascular endothelium) | CDH5 | –2 | .0018 |
| 265 | 11096 | ADAM metallopeptidase with thrombospondin type 1 motif, 5 | ADAMTS5 | –3.2 | .0018 |
| 266 | 55328 | Chromosome 10 open reading frame 59 | C10orf59 | –1.5 | .0018 |
| 267 | 925 | CD8a molecule | CD8A | –2 | .0018 |
| 268 | 60489 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | APOBEC3G | –1.7 | .0018 |
| 269 | 244 | Annexin A8-like 2 | ANXA8L2 | 1.9 | .0019 |
| 270 | 54769 | DIRAS family, GTP-binding RAS-like 2 | DIRAS2 | –1.6 | .0019 |
| 271 | 919 | CD247 molecule | CD247 | –2 | .0019 |
| 272 | 2289 | FK506 binding protein 5 | FKBP5 | –1.6 | .0019 |
| 273 | 2532 | Duffy blood group, chemokine receptor | DARC | –2.3 | .002 |
| 274 | 6582 | Solute carrier family 22 (organic cation transporter), member 2 | SLC22A2 | 1.8 | .002 |
| 275 | 3489 | Insulin-like growth factor binding protein 6 | IGFBP6 | –2.3 | .002 |
| 276 | 78989 | Collectin sub-family member 11 | COLEC11 | –1.9 | .002 |
| 277 | 56521 | Dnaj (Hsp40) homolog, subfamily C, member 12 | DNAJC12 | –1.7 | .002 |
| 278 | 9322 | Thyroid hormone receptor interactor 10 | TRIP10 | 1.5 | .002 |
| 279 | 164284 | Adenomatosis polyposis coli down-regulated 1-like | APCDD1L | 2 | .0021 |
| 280 | 652891 | Similar to Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta) (VAC-beta) | LOC652891 | 1.9 | .0021 |
| 281 | 10631 | Periostin, osteoblast specific factor | POSTN | –1.9 | .0021 |
| 282 | 3115 | Major histocompatibility complex, class II, DP beta 1 | HLA-DPB1 | –1.5 | .0021 |
| 283 | 3772 | Potassium inwardly-rectifying channel, subfamily J, member 15 | KCNJ15 | 1.5 | .0021 |
| 284 | 728215 | Family with sequence similarity 155, member A | FAM155A | –1.9 | .0022 |
| 285 | 65009 | NDRG family member 4 | NDRG4 | –1.5 | .0022 |
| 286 | 256236 | Napsin B aspartic peptidase pseudogene | NAPSB | –2.1 | .0022 |
| 287 | 2534 | FYN oncogene related to SRC, FGR, YES | FYN | –1.5 | .0022 |
| 288 | 399888 | Family with sequence similarity 180, member B | FAM180B | –1.6 | .0022 |
| 289 | 2150 | Coagulation factor II (thrombin) receptor-like 1 | F2RL1 | 1.6 | .0022 |
| 290 | 26137 | Zinc finger and BTB domain containing 20 | ZBTB20 | –1.5 | .0022 |
| 291 | 255488 | Ring finger protein 144B | RNF144B | 1.7 | .0022 |
| 292 | 140880 | Cystatin 11 | CST11 | –1.7 | .0022 |
| 293 | 4504 | Metallothionein 3 | MT3 | 1.6 | .0022 |
| 294 | 6781 | Stanniocalcin 1 | STC1 | 1.6 | .0023 |
| 295 | 5023 | Purinergic receptor P2X, ligand-gated ion channel, 1 | P2RX1 | 1.6 | .0023 |
| 296 | 64838 | Fibronectin type III domain containing 4 | FNDC4 | –1.6 | .0023 |
| 297 | 915 | CD3d molecule, delta (CD3-TCR complex) | CD3D | –1.9 | .0023 |
| 298 | 1307 | Collagen, type XVI, alpha 1 | COL16A1 | 2.1 | .0023 |
| 299 | 5175 | Platelet/endothelial cell adhesion molecule | PECAM1 | –1.8 | .0023 |
| 300 | 23362 | Pleckstrin and Sec7 domain containing 3 | PSD3 | –1.5 | .0024 |
| 301 | 919 | CD247 molecule | CD247 | –2 | .0024 |
| 302 | 89932 | Papilin, proteoglycan-like sulfated glycoprotein | PAPLN | –2.2 | .0024 |
| 303 | 5144 | Phosphodiesterase 4D, camp-specific (phosphodiesterase E3 dunce homolog, Drosophila ) | PDE4D | 1.7 | .0024 |
| 304 | 3918 | Laminin, gamma 2 | LAMC2 | 2.2 | .0024 |
| 305 | 10537 | Ubiquitin D | UBD | –1.9 | .0024 |
| 306 | 3002 | Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | GZMB | –2.6 | .0024 |
| 307 | 2244 | Fibrinogen beta chain | FGB | –2.1 | .0024 |
| 308 | 51129 | Angiopoietin-like 4 | ANGPTL4 | 1.7 | .0024 |
| 309 | 623 | Bradykinin receptor B1 | BDKRB1 | 2.1 | .0024 |
| 310 | 79037 | Poliovirus receptor related immunoglobulin domain containing | PVRIG | –1.5 | .0024 |
| 311 | 27075 | Tetraspanin 13 | TSPAN13 | 1.6 | .0024 |
| 312 | 5047 | Progestagen-associated endometrial protein | PAEP | –3.9 | .0024 |
| 313 | 25827 | F-box and leucine-rich repeat protein 2 | FBXL2 | –1.5 | .0025 |
| 314 | 55971 | BAI1-associated protein 2-like 1 | BAIAP2L1 | 1.7 | .0025 |
| 315 | 1281 | Collagen, type III, alpha 1 | COL3A1 | 2.2 | .0025 |
| 316 | 10276 | Neuroepithelial cell transforming 1 | NET1 | 1.7 | .0025 |
| 317 | 51312 | Solute carrier family 25, member 37 | SLC25A37 | 1.6 | .0025 |
| 318 | 11309 | Solute carrier organic anion transporter family, member 2B1 | SLCO2B1 | –1.8 | .0025 |
| 319 | 10149 | G protein-coupled receptor 64 | GPR64 | –1.8 | .0025 |
| 320 | 1837 | Dystrobrevin, alpha | DTNA | –1.6 | .0025 |
| 321 | 335 | Apolipoprotein A-I | APOA1 | –2.2 | .0025 |
| 322 | 10964 | Interferon-induced protein 44-like | IFI44L | –1.9 | .0026 |
| 323 | 1289 | Collagen, type V, alpha 1 | COL5A1 | 1.6 | .0026 |
| 324 | 1301 | Collagen, type XI, alpha 1 | COL11A1 | 1.9 | .0026 |
| 325 | 164832 | LON peptidase N-terminal domain and ring finger 2 | LONRF2 | –2 | .0026 |
| 326 | 10268 | Receptor (G protein-coupled) activity modifying protein 3 | RAMP3 | –1.9 | .0027 |
| 327 | 9536 | Prostaglandin E synthase | PTGES | 1.6 | .0027 |
| 328 | 6581 | Solute carrier family 22 (extraneuronal monoamine transporter), member 3 | SLC22A3 | 1.7 | .0028 |
| 329 | 2266 | Fibrinogen gamma chain | FGG | –2.2 | .0028 |
| 330 | 3664 | Interferon regulatory factor 6 | IRF6 | 1.5 | .0028 |
| 331 | 3945 | Lactate dehydrogenase B | LDHB | –1.6 | .0028 |
| 332 | 9843 | Hephaestin | HEPH | –1.7 | .0029 |
| 333 | 9459 | Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 | ARHGEF6 | –1.7 | .0029 |
| 334 | 3751 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | KCND2 | –1.6 | .0029 |
| 335 | 3384 | Intercellular adhesion molecule 2 | ICAM2 | –1.7 | .0029 |
| 336 | 3206 | Homeobox A10 | HOXA10 | –1.5 | .0029 |
| 337 | 84985 | Family with sequence similarity 83, member A | FAM83A | 2.2 | .0029 |
| 338 | 3914 | Laminin, beta 3 | LAMB3 | 2.2 | .003 |
| 339 | 1308 | Collagen, type XVII, alpha 1 | COL17A1 | 1.9 | .0031 |
| 340 | 9806 | Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 | SPOCK2 | –2.9 | .0032 |
| 341 | 481 | Atpase, Na+/K+ transporting, beta 1 polypeptide | ATP1B1 | 1.6 | .0032 |
| 342 | 712 | Complement component 1, q subcomponent, A chain | C1QA | –1.8 | .0033 |
| 343 | 79669 | Chromosome 3 open reading frame 52 | C3orf52 | 1.6 | .0033 |
| 344 | 56901 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 | NDUFA4L2 | 1.9 | .0034 |
| 345 | 6764 | Suppression of tumorigenicity 5 | ST5 | 1.5 | .0035 |
| 346 | 10894 | Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1 | –1.7 | .0035 |
| 347 | 1847 | Dual specificity phosphatase 5 | DUSP5 | 1.7 | .0035 |
| 348 | 54587 | Matrix-remodelling associated 8 | MXRA8 | –1.6 | .0035 |
| 349 | 2243 | Fibrinogen alpha chain | FGA | –1.9 | .0035 |
| 350 | 55959 | Sulfatase 2 | SULF2 | –2.3 | .0035 |
| 351 | 22943 | Dickkopf homolog 1 (Xenopus laevis) | DKK1 | –1.9 | .0036 |
| 352 | 122786 | FERM domain containing 6 | FRMD6 | 1.6 | .0037 |
| 353 | 5420 | Podocalyxin-like | PODXL | –2.3 | .0037 |
| 354 | 5307 | Paired-like homeodomain 1 | PITX1 | 1.7 | .0038 |
| 355 | 3695 | Integrin, beta 7 | ITGB7 | –1.7 | .0038 |
| 356 | 3805 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 | KIR2DL4 | –1.5 | .0038 |
| 357 | 668 | Forkhead box L2 | FOXL2 | –1.8 | .0038 |
| 358 | 54 | Acid phosphatase 5, tartrate resistant | ACP5 | –1.7 | .0038 |
| 359 | 107 | Adenylate cyclase 1 (brain) | ADCY1 | –1.8 | .0039 |
| 360 | 166929 | Sphingomyelin synthase 2 | SGMS2 | 1.6 | .004 |
| 361 | 10276 | Neuroepithelial cell transforming 1 | NET1 | 1.6 | .004 |
| 362 | 8507 | Ectodermal-neural cortex (with BTB-like domain) | ENC1 | 1.5 | .0041 |
| 363 | 5744 | Parathyroid hormone-like hormone | PTHLH | 2.5 | .0041 |
| 364 | 5091 | Pyruvate carboxylase | PC | –1.6 | .0041 |
| 365 | 5627 | Protein S (alpha) | PROS1 | –1.8 | .0041 |
| 366 | 4907 | 5′-nucleotidase, ecto (CD73) | NT5E | 1.5 | .0041 |
| 367 | 55959 | Sulfatase 2 | SULF2 | –2.2 | .0041 |
| 368 | 286133 | Scavenger receptor class A, member 5 (putative) | SCARA5 | –4.3 | .0042 |
| 369 | 147495 | Adenomatosis polyposis coli down-regulated 1 | APCDD1 | –2 | .0042 |
| 370 | 1308 | Collagen, type XVII, alpha 1 | COL17A1 | 1.6 | .0043 |
| 371 | 56521 | Dnaj (Hsp40) homolog, subfamily C, member 12 | DNAJC12 | –1.7 | .0044 |
| 372 | 80310 | Platelet derived growth factor D | PDGFD | –1.6 | .0044 |
| 373 | 3109 | Major histocompatibility complex, class II, DM beta | HLA-DMB | –2 | .0044 |
| 374 | 4920 | Receptor tyrosine kinase-like orphan receptor 2 | ROR2 | –1.7 | .0044 |
| 375 | 3902 | Lymphocyte-activation gene 3 | LAG3 | –1.5 | .0044 |
| 376 | 5156 | Platelet-derived growth factor receptor, alpha polypeptide | PDGFRA | –1.7 | .0044 |
| 377 | 6242 | Rhotekin | RTKN | 1.6 | .0044 |
| 378 | 8061 | FOS-like antigen 1 | FOSL1 | 1.7 | .0044 |
| 379 | 56521 | Dnaj (Hsp40) homolog, subfamily C, member 12 | DNAJC12 | –1.7 | .0044 |
| 380 | 7026 | Nuclear receptor subfamily 2, group F, member 2 | NR2F2 | –1.7 | .0044 |
| 381 | 84969 | TOX high mobility group box family member 2 | TOX2 | –1.7 | .0044 |
| 382 | 8870 | Immediate early response 3 | IER3 | 2.1 | .0044 |
| 383 | 55303 | Gtpase, IMAP family member 4 | GIMAP4 | –2.1 | .0045 |
| 384 | 4818 | Natural killer cell group 7 sequence | NKG7 | –2.4 | .0045 |
| 385 | 154214 | Ring finger protein 217 | RNF217 | 1.6 | .0045 |
| 386 | 729682 | Keratin 17 pseudogene 3 | KRT17P3 | 2.5 | .0045 |
| 387 | 729345 | Hypothetical LOC729345 | LOC729345 | –1.5 | .0046 |
| 388 | 100132916 | Family with sequence similarity 159, member B | FAM159B | –1.8 | .0046 |
| 389 | 5743 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | PTGS2 | 2.1 | .0046 |
| 390 | 1593 | Cytochrome P450, family 27, subfamily A, polypeptide 1 | CYP27A1 | –1.7 | .0046 |
| 391 | 1672 | Defensin, beta 1 | DEFB1 | –2.9 | .0046 |
| 392 | 57484 | Ring finger protein 150 | RNF150 | –1.8 | .0047 |
| 393 | 152273 | FYVE, rhogef and PH domain containing 5 | FGD5 | –2 | .0047 |
| 394 | 3600 | Interleukin 15 | IL15 | –2.4 | .0048 |
| 395 | 481 | Atpase, Na+/K+ transporting, beta 1 polypeptide | ATP1B1 | 1.6 | .0048 |
| 396 | 3755 | Potassium voltage-gated channel, subfamily G, member 1 | KCNG1 | 1.5 | .0049 |
| 397 | 256236 | Napsin B aspartic peptidase pseudogene | NAPSB | –1.6 | .0049 |
| 398 | 81617 | Calcium binding protein 39-like | CAB39L | –1.8 | .0049 |
| 399 | 3854 | Keratin 6B | KRT6B | 2.2 | .005 |
| 400 | 286077 | Family with sequence similarity 83, member H | FAM83H | 1.5 | .0051 |
| 401 | 29992 | Paired immunoglobin-like type 2 receptor alpha | PILRA | –1.9 | .0051 |
| 402 | 383 | Arginase, liver | ARG1 | –2.1 | .0051 |
| 403 | 5095 | Propionyl Coenzyme A carboxylase, alpha polypeptide | PCCA | –2.1 | .0051 |
| 404 | 54463 | Family with sequence similarity 134, member B | FAM134B | –1.7 | .0052 |
| 405 | 4147 | Matrilin 2 | MATN2 | 2 | .0052 |
| 406 | 25903 | Olfactomedin-like 2B | OLFML2B | –1.7 | .0052 |
| 407 | 8611 | Phosphatidic acid phosphatase type 2A | PPAP2A | –1.6 | .0052 |
| 408 | 10848 | Protein phosphatase 1, regulatory (inhibitor) subunit 13 like | PPP1R13L | 1.5 | .0053 |
| 409 | 486 | FXYD domain containing ion transport regulator 2 | FXYD2 | –1.6 | .0053 |
| 410 | 81617 | Calcium binding protein 39-like | CAB39L | –1.8 | .0053 |
| 411 | 420 | ADP-ribosyltransferase 4 (Dombrock blood group) | ART4 | 1.7 | .0054 |
| 412 | 109 | Adenylate cyclase 3 | ADCY3 | –1.9 | .0054 |
| 413 | 163183 | Chromosome 19 open reading frame 46 | C19orf46 | 1.5 | .0054 |
| 414 | 8613 | Phosphatidic acid phosphatase type 2B | PPAP2B | –1.9 | .0054 |
| 415 | 3202 | Homeobox A5 | HOXA5 | –2.5 | .0055 |
| 416 | 11309 | Solute carrier organic anion transporter family, member 2B1 | SLCO2B1 | –1.9 | .0056 |
| 417 | 1909 | Endothelin receptor type A | EDNRA | –1.7 | .0056 |
| 418 | 7371 | Uridine-cytidine kinase 2 | UCK2 | 1.6 | .0057 |
| 419 | 794 | Calbindin 2 | CALB2 | 1.6 | .0057 |
| 420 | 29091 | Syntaxin binding protein 6 (amisyn) | STXBP6 | 1.8 | .0057 |
| 421 | 3157 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) | HMGCS1 | 1.5 | .0057 |
| 422 | 492 | Atpase, Ca++ transporting, plasma membrane 3 | ATP2B3 | –1.5 | .0059 |
| 423 | 2619 | Growth arrest-specific 1 | GAS1 | –2.5 | .0059 |
| 424 | 60370 | Arginine vasopressin-induced 1 | AVPI1 | –1.6 | .006 |
| 425 | 5744 | Parathyroid hormone-like hormone | PTHLH | 2.3 | .006 |
| 426 | 9882 | TBC1 domain family, member 4 | TBC1D4 | –1.6 | .0061 |
| 427 | 84913 | Atonal homolog 8 ( Drosophila ) | ATOH8 | –2.3 | .0061 |
| 428 | 8835 | Suppressor of cytokine signaling 2 | SOCS2 | –1.6 | .0061 |
| 429 | 4629 | Myosin, heavy chain 11, smooth muscle | MYH11 | –2.7 | .0062 |
| 430 | 2922 | Gastrin-releasing peptide | GRP | 2.1 | .0062 |
| 431 | 51083 | Galanin prepropeptide | GAL | –2.4 | .0062 |
| 432 | 5091 | Pyruvate carboxylase | PC | –1.7 | .0062 |
| 433 | 3543 | Immunoglobulin lambda-like polypeptide 1 | IGLL1 | –1.9 | .0062 |
| 434 | 1474 | Cystatin E/M | CST6 | 2.3 | .0062 |
| 435 | 10561 | Interferon-induced protein 44 | IFI44 | –1.6 | .0062 |
| 436 | 140738 | Transmembrane protein 37 | TMEM37 | –2.4 | .0062 |
| 437 | 84034 | Elastin microfibril interfacer 2 | EMILIN2 | –1.5 | .0062 |
| 438 | 64926 | RAS protein activator like 3 | RASAL3 | –1.6 | .0062 |
| 439 | 80310 | Platelet derived growth factor D | PDGFD | –1.6 | .0063 |
| 440 | 716 | Complement component 1, s subcomponent | C1S | –1.7 | .0063 |
| 441 | 3918 | Laminin, gamma 2 | LAMC2 | 2 | .0064 |
| 442 | 5047 | Progestagen-associated endometrial protein | PAEP | –4.1 | .0064 |
| 443 | 3732 | CD82 molecule | CD82 | –1.5 | .0065 |
| 444 | 3159 | High mobility group AT-hook 1 | HMGA1 | 1.6 | .0065 |
| 445 | 100133678 | Similar to hcg2042724 | LOC100133678 | –2.2 | .0065 |
| 446 | 125228 | Chromosome 18 open reading frame 19 | C18orf19 | 1.6 | .0066 |
| 447 | 3128 | Major histocompatibility complex, class II, DR beta 6 (pseudogene) | HLA-DRB6 | –1.6 | .0066 |
| 448 | 7490 | Wilms tumor 1 | WT1 | –2.2 | .0066 |
| 449 | 27295 | PDZ and LIM domain 3 | PDLIM3 | 1.8 | .0066 |
| 450 | 55612 | Fermitin family homolog 1 ( Drosophila ) | FERMT1 | 1.5 | .0067 |
| 451 | 2769 | Guanine nucleotide binding protein (G protein), alpha 15 (Gq class) | GNA15 | 1.7 | .0068 |
| 452 | 7140 | Troponin T type 3 (skeletal, fast) | TNNT3 | 1.8 | .0068 |
| 453 | 4256 | Matrix Gla protein | MGP | –2.6 | .007 |
| 454 | 2040 | Stomatin | STOM | –1.5 | .0071 |
| 455 | 3621 | Inhibitor of growth family, member 1 | ING1 | –1.8 | .0071 |
| 456 | 4092 | SMAD family member 7 | SMAD7 | 1.5 | .0072 |
| 457 | 2243 | Fibrinogen alpha chain | FGA | –2.1 | .0072 |
| 458 | 4803 | Nerve growth factor (beta polypeptide) | NGF | 1.6 | .0072 |
| 459 | 1277 | Collagen, type I, alpha 1 | COL1A1 | 2.6 | .0072 |
| 460 | 5268 | Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | SERPINB5 | 2.3 | .0072 |
| 461 | 217 | Aldehyde dehydrogenase 2 family (mitochondrial) | ALDH2 | –1.7 | .0072 |
| 462 | 652493 | Similar to immunoglobulin kappa chain V-I region HK102 precursor | LOC652493 | –1.6 | .0072 |
| 463 | 112616 | CKLF-like MARVEL transmembrane domain containing 7 | CMTM7 | –1.6 | .0073 |
| 464 | 8829 | Neuropilin 1 | NRP1 | –1.6 | .0073 |
| 465 | 7348 | Uroplakin 1B | UPK1B | 2 | .0074 |
| 466 | 7177 | Tryptase alpha/beta 1 | TPSAB1 | –1.9 | .0075 |
| 467 | 3875 | Keratin 18 | KRT18 | 1.7 | .0075 |
| 468 | 3868 | Keratin 16 | KRT16 | 2.3 | .0075 |
| 469 | 358 | Aquaporin 1 (Colton blood group) | AQP1 | 1.7 | .0076 |
| 470 | 768 | Carbonic anhydrase IX | CA9 | 1.6 | .0076 |
| 471 | 3576 | Interleukin 8 | IL8 | 2 | .0077 |
| 472 | 8614 | Stanniocalcin 2 | STC2 | 1.9 | .0078 |
| 473 | 221472 | FYVE, rhogef and PH domain containing 2 | FGD2 | –1.6 | .0078 |
| 474 | 2318 | Filamin C, gamma (actin binding protein 280) | FLNC | 2 | .0082 |
| 475 | 10570 | Dihydropyrimidinase-like 4 | DPYSL4 | 1.6 | .0083 |
| 476 | 57568 | Signal-induced proliferation-associated 1 like 2 | SIPA1L2 | –1.9 | .0083 |
| 477 | 10268 | Receptor (G protein-coupled) activity modifying protein 3 | RAMP3 | –1.6 | .0084 |
| 478 | 3108 | Major histocompatibility complex, class II, DM alpha | HLA-DMA | –1.7 | .0084 |
| 479 | 10809 | Star-related lipid transfer (START) domain containing 10 | STARD10 | 1.5 | .0084 |
| 480 | 59271 | Chromosome 21 open reading frame 63 | C21orf63 | –1.9 | .0085 |
| 481 | 220323 | OAF homolog ( Drosophila ) | OAF | –2.3 | .0085 |
| 482 | 11031 | RAB31, member RAS oncogene family | RAB31 | –1.6 | .0087 |
| 483 | 55803 | Arfgap with dual PH domains 2 | ADAP2 | –1.6 | .0087 |
| 484 | 4256 | Matrix Gla protein | MGP | –2.4 | .0088 |
| 485 | 57611 | Immunoglobulin superfamily containing leucine-rich repeat 2 | ISLR2 | –1.6 | .0088 |
| 486 | 4217 | Mitogen-activated protein kinase kinase kinase 5 | MAP3K5 | –1.9 | .0088 |
| 487 | 7280 | Tubulin, beta 2A | TUBB2A | 1.6 | .0089 |
| 488 | 114902 | C1q and tumor necrosis factor related protein 5 | C1QTNF5 | –1.8 | .0092 |
| 489 | 5210 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 | PFKFB4 | 1.5 | .0092 |
| 490 | 8363 | Histone cluster 1, h4j | HIST1H4J | –1.6 | .0092 |
| 491 | 629 | Complement factor B | CFB | 1.9 | .0092 |
| 492 | 9476 | Napsin A aspartic peptidase | NAPSA | –1.7 | .0093 |
| 493 | 5918 | Retinoic acid receptor responder (tazarotene induced) 1 | RARRES1 | –1.9 | .0093 |
| 494 | 3671 | Immunoglobulin superfamily containing leucine-rich repeat | ISLR | –1.9 | .0094 |
| 495 | 2350 | Folate receptor 2 (fetal) | FOLR2 | –1.6 | .0095 |
| 496 | 100133583 | Similar to major histocompatibility complex, class II, DQ beta 1 | LOC100133583 | –1.8 | .0095 |
| 497 | 1829 | Desmoglein 2 | DSG2 | 1.6 | .0095 |
| 498 | 116039 | Odd-skipped related 2 ( Drosophila ) | OSR2 | –1.7 | .0096 |
| 499 | 5602 | Mitogen-activated protein kinase 10 | MAPK10 | –1.5 | .0096 |
| 500 | 152992 | Chromosome 4 open reading frame 23 | C4orf23 | –1.6 | .0096 |
| 501 | 9379 | Neurexin 2 | NRXN2 | –1.8 | .0096 |
| 502 | 10252 | Sprouty homolog 1, antagonist of FGF signaling ( Drosophila ) | SPRY1 | –1.6 | .0096 |
| 503 | 1288 | Collagen, type IV, alpha 6 | COL4A6 | –1.5 | .0097 |
| 504 | 1294 | Collagen, type VII, alpha 1 | COL7A1 | 1.8 | .0097 |
| 505 | 341 | Apolipoprotein C-I | APOC1 | –1.8 | .01 |
| 506 | 5918 | Retinoic acid receptor responder (tazarotene induced) 1 | RARRES1 | –1.6 | .01 |
| 507 | 55344 | Phosphatidylinositol-specific phospholipase C, X domain containing 1 | PLCXD1 | 1.6 | .011 |
| 508 | 7177 | Tryptase alpha/beta 1 | TPSAB1 | –2.1 | .011 |
| 509 | 1474 | Cystatin E/M | CST6 | 2.2 | .011 |
| 510 | 221830 | TWIST neighbor | TWISTNB | –1.6 | .011 |
| 511 | 7490 | Wilms tumor 1 | WT1 | –2.3 | .011 |
| 512 | 5618 | Prolactin receptor | PRLR | –1.7 | .011 |
| 513 | 100133914 | Hypothetic protein LOC100133914 | LOC100133914 | 1.5 | .011 |
| 514 | 120939 | Chromosome 12 open reading frame 59 | C12orf59 | 1.5 | .011 |
| 515 | 2619 | Growth arrest-specific 1 | GAS1 | –2.5 | .011 |
| 516 | 54463 | Family with sequence similarity 134, member B | FAM134B | –1.5 | .011 |
| 517 | 3373 | Hyaluronoglucosaminidase 1 | HYAL1 | –1.5 | .011 |
| 518 | 441519 | Cancer/testis antigen CT45-3 | RP13-36C9.3 | 1.6 | .011 |
| 519 | 91937 | T-cell immunoglobulin and mucin domain containing 4 | TIMD4 | –1.6 | .011 |
| 520 | 8536 | Calcium/calmodulin-dependent protein kinase I | CAMK1 | –1.5 | .011 |
| 521 | 81035 | Collectin sub-family member 12 | COLEC12 | –1.7 | .011 |
| 522 | 8613 | Phosphatidic acid phosphatase type 2B | PPAP2B | –1.7 | .011 |
| 523 | 5743 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | PTGS2 | 2 | .011 |
| 524 | 3126 | Major histocompatibility complex, class II, DR beta 4 | HLA-DRB4 | –2 | .011 |
| 525 | 100133643 | Hypothetic protein LOC100133643 | LOC100133643 | –1.5 | .011 |
| 526 | 4192 | Midkine (neurite growth-promoting factor 2) | MDK | –2.3 | .011 |
| 527 | 9242 | Musculin (activated B-cell factor-1) | MSC | 1.6 | .011 |
| 528 | 9547 | Chemokine (C-X-C motif) ligand 14 | CXCL14 | –2.3 | .011 |
| 529 | 726 | Calpain 5 | CAPN5 | –1.8 | .011 |
| 530 | 714 | Complement component 1, q subcomponent, C chain | C1QC | –2.1 | .012 |
| 531 | 1503 | CTP synthase | CTPS | 1.6 | .012 |
| 532 | 7453 | Tryptophanyl-trna synthetase | WARS | –1.6 | .012 |
| 533 | 3854 | Keratin 6B | KRT6B | 2.2 | .012 |
| 534 | 26056 | RAB11 family interacting protein 5 (class I) | RAB11FIP5 | 1.5 | .012 |
| 535 | 139221 | Melanoma associated antigen (mutated) 1-like 1 | MUM1L1 | –1.6 | .012 |
| 536 | 8463 | TEA domain family member 2 | TEAD2 | –1.5 | .012 |
| 537 | 10875 | Fibrinogen-like 2 | FGL2 | –1.8 | .012 |
| 538 | 8646 | Chordin | CHRD | –1.5 | .012 |
| 539 | 147920 | IGF-like family member 2 | IGFL2 | 1.9 | .012 |
| 540 | 3909 | Laminin, alpha 3 | LAMA3 | 1.7 | .012 |
| 541 | 10252 | Sprouty homolog 1, antagonist of FGF signaling ( Drosophila ) | SPRY1 | –1.6 | .012 |
| 542 | 306 | Annexin A3 | ANXA3 | 1.7 | .012 |
| 543 | 1268 | Cannabinoid receptor 1 (brain) | CNR1 | –2.3 | .012 |
| 544 | 10653 | Serine peptidase inhibitor, Kunitz type, 2 | SPINT2 | 1.7 | .013 |
| 545 | 8611 | Phosphatidic acid phosphatase type 2A | PPAP2A | –2.3 | .013 |
| 546 | 57817 | Hepcidin antimicrobial peptide | HAMP | –1.9 | .013 |
| 547 | 1278 | Collagen, type I, alpha 2 | COL1A2 | 2.2 | .013 |
| 548 | 3557 | Interleukin 1 receptor antagonist | IL1RN | 3 | .013 |
| 549 | 22801 | Integrin, alpha 11 | ITGA11 | 1.6 | .013 |
| 550 | 2 | Alpha-2-macroglobulin | A2M | –2.1 | .013 |
| 551 | 23179 | Ral guanine nucleotide dissociation stimulator-like 1 | RGL1 | –1.8 | .013 |
| 552 | 3824 | Killer cell lectin-like receptor subfamily D, member 1 | KLRD1 | –1.6 | .013 |
| 553 | 10644 | Insulin-like growth factor 2 mRNA binding protein 2 | IGF2BP2 | 1.6 | .013 |
| 554 | 7140 | Troponin T type 3 (skeletal, fast) | TNNT3 | 1.7 | .013 |
| 555 | 29995 | LIM and cysteine-rich domains 1 | LMCD1 | 1.6 | .013 |
| 556 | 639 | PR domain containing 1, with ZNF domain | PRDM1 | –1.8 | .014 |
| 557 | 716 | Complement component 1, s subcomponent | C1S | –1.8 | .014 |
| 558 | 1359 | Carboxypeptidase A3 (mast cell) | CPA3 | –1.7 | .014 |
| 559 | 3113 | Major histocompatibility complex, class II, DP alpha 1 | HLA-DPA1 | –1.9 | .014 |
| 560 | 84985 | Family with sequence similarity 83, member A | FAM83A | 1.9 | .014 |
| 561 | 3481 | Insulin-like growth factor 2 (somatomedin A) | IGF2 | 1.6 | .014 |
| 562 | 3481 | Insulin-like growth factor 2 (somatomedin A) | IGF2 | 1.6 | .014 |
| 563 | 348 | Apolipoprotein E | APOE | –2.6 | .014 |
| 564 | 27299 | ADAM-like, decysin 1 | ADAMDEC1 | –2.2 | .014 |
| 565 | 972 | CD74 molecule, major histocompatibility complex, class II invariant chain | CD74 | –1.8 | .015 |
| 566 | 56475 | Reprimo, TP53 dependent G2 arrest mediator candidate | RPRM | –1.9 | .015 |
| 567 | 64073 | Chromosome 19 open reading frame 33 | C19orf33 | 2.1 | .015 |
| 568 | 25907 | Transmembrane protein 158 | TMEM158 | 2 | .015 |
| 569 | 85415 | Rhophilin, Rho gtpase binding protein 2 | RHPN2 | 1.6 | .015 |
| 570 | 6364 | Chemokine (C-C motif) ligand 20 | CCL20 | 2.6 | .015 |
| 571 | 1000 | Cadherin 2, type 1, N-cadherin (neuronal) | CDH2 | 1.7 | .015 |
| 572 | 59277 | Netrin 4 | NTN4 | –1.8 | .015 |
| 573 | 10318 | TNFAIP3 interacting protein 1 | TNIP1 | 1.5 | .015 |
| 574 | 10391 | Coronin, actin binding protein, 2B | CORO2B | –1.5 | .015 |
| 575 | 8854 | Aldehyde dehydrogenase 1 family, member A2 | ALDH1A2 | –2.8 | .015 |
| 576 | 81848 | Sprouty homolog 4 ( Drosophila ) | SPRY4 | 1.5 | .016 |
| 577 | 9464 | Heart and neural crest derivatives expressed 2 | HAND2 | –1.8 | .016 |
| 578 | 2308 | Forkhead box O1 | FOXO1 | –1.8 | .016 |
| 579 | 4147 | Matrilin 2 | MATN2 | 1.7 | .016 |
| 580 | 3909 | Laminin, alpha 3 | LAMA3 | 1.7 | .016 |
| 581 | 5996 | Regulator of G-protein signaling 1 | RGS1 | –1.7 | .016 |
| 582 | 650405 | Similar to Ig kappa chain V-I region HK102 precursor | LOC650405 | –1.6 | .016 |
| 583 | 51352 | Wilms tumor upstream neighbor 1 | WIT1 | –1.8 | .016 |
| 584 | 4739 | Neural precursor cell expressed, developmentally down-regulated 9 | NEDD9 | 1.7 | .016 |
| 585 | 85004 | RAS-like, estrogen-regulated, growth inhibitor | RERG | –1.5 | .017 |
| 586 | 8842 | Prominin 1 | PROM1 | –1.8 | .017 |
| 587 | 8611 | Phosphatidic acid phosphatase type 2A | PPAP2A | –2.2 | .017 |
| 588 | 1043 | CD52 molecule | CD52 | –2.2 | .017 |
| 589 | 3569 | Interleukin 6 (interferon, beta 2) | IL6 | 2.7 | .017 |
| 590 | 10170 | Dehydrogenase/reductase (SDR family) member 9 | DHRS9 | –1.7 | .017 |
| 591 | 7124 | Tumor necrosis factor (TNF superfamily, member 2) | TNF | 2.3 | .017 |
| 592 | 7262 | Pleckstrin homology-like domain, family A, member 2 | PHLDA2 | 1.6 | .018 |
| 593 | 59342 | Serine carboxypeptidase 1 | SCPEP1 | –1.7 | .018 |
| 594 | 1842 | Extracellular matrix protein 2, female organ and adipocyte specific | ECM2 | –1.6 | .018 |
| 595 | 7033 | Trefoil factor 3 (intestinal) | TFF3 | –2.5 | .018 |
| 596 | 54596 | LINE-1 type transposase domain containing 1 | L1TD1 | 1.5 | .018 |
| 597 | 6096 | RAR-related orphan receptor B | RORB | –2.5 | .018 |
| 598 | 1513 | Cathepsin K | CTSK | –2.7 | .018 |
| 599 | 79804 | Nbla00301 | NBLA00301 | –2 | .018 |
| 600 | 2707 | Gap junction protein, beta 3, 31 kd | GJB3 | 1.7 | .018 |
| 601 | 221895 | JAZF zinc finger 1 | JAZF1 | –1.6 | .018 |
| 602 | 713 | Complement component 1, q subcomponent, B chain | C1QB | –1.9 | .018 |
| 603 | 113457 | Tubulin, alpha 3d | TUBA3D | –1.8 | .018 |
| 604 | 29984 | Ras homolog gene family, member D | RHOD | 1.7 | .019 |
| 605 | 439921 | Matrix-remodelling associated 7 | MXRA7 | –1.9 | .019 |
| 606 | 1290 | Collagen, type V, alpha 2 | COL5A2 | 1.9 | .019 |
| 607 | 84525 | HOP homeobox | HOPX | –1.6 | .019 |
| 608 | 972 | CD74 molecule, major histocompatibility complex, class II invariant chain | CD74 | –1.7 | .019 |
| 609 | 10044 | SH2 domain containing 3C | SH2D3C | –1.5 | .019 |
| 610 | 999 | Cadherin 1, type 1, E-cadherin (epithelial) | CDH1 | 1.5 | .019 |
| 611 | 10235 | RAS guanyl releasing protein 2 (calcium and DAG-regulated) | RASGRP2 | –1.7 | .019 |
| 612 | 10930 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 | APOBEC2 | 1.6 | .019 |
| 613 | 5174 | PDZ domain containing 1 | PDZK1 | 1.6 | .02 |
| 614 | 8605 | Phospholipase A2, group IVC (cytosolic, calcium-independent) | PLA2G4C | –1.6 | .02 |
| 615 | 1969 | EPH receptor A2 | EPHA2 | 1.6 | .02 |
| 616 | 116039 | Odd-skipped related 2 ( Drosophila ) | OSR2 | –2.2 | .02 |
| 617 | 7869 | Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B | SEMA3B | –1.6 | .02 |
| 618 | 23396 | Phosphatidylinositol-4-phosphate 5-kinase, type I, gamma | PIP5K1C | –1.6 | .02 |
| 619 | 864 | Runt-related transcription factor 3 | RUNX3 | –1.6 | .02 |
| 620 | 1536 | Cytochrome b-245, beta polypeptide | CYBB | –1.6 | .02 |
| 621 | 29992 | Paired immunoglobin-like type 2 receptor alpha | PILRA | –1.7 | .02 |
| 622 | 112714 | Tubulin, alpha 3e | TUBA3E | –1.9 | .021 |
| 623 | 3123 | Major histocompatibility complex, class II, DR beta 1 | HLA-DRB1 | –1.8 | .021 |
| 624 | 80115 | BAI1-associated protein 2-like 2 | BAIAP2L2 | –1.7 | .021 |
| 625 | 4246 | Secretoglobin, family 2A, member 1 | SCGB2A1 | –1.9 | .021 |
| 626 | 94274 | Protein phosphatase 1, regulatory (inhibitor) subunit 14A | PPP1R14A | –1.6 | .021 |
| 627 | 349136 | WD repeat domain 86 | WDR86 | –1.6 | .021 |
| 628 | 9414 | Tight junction protein 2 (zona occludens 2) | TJP2 | 1.6 | .021 |
| 629 | 1318 | Solute carrier family 31 (copper transporters), member 2 | SLC31A2 | –1.8 | .022 |
| 630 | 9245 | Glucosaminyl (N-acetyl) transferase 3, mucin type | GCNT3 | –1.6 | .022 |
| 631 | 27129 | Heat shock 27 kd protein family, member 7 (cardiovascular) | HSPB7 | 1.7 | .022 |
| 632 | 7057 | Thrombospondin 1 | THBS1 | 2 | .022 |
| 633 | 7278 | Tubulin, alpha 3c | TUBA3C | –1.7 | .022 |
| 634 | 27299 | ADAM-like, decysin 1 | ADAMDEC1 | –1.7 | .023 |
| 635 | 57111 | RAB25, member RAS oncogene family | RAB25 | 1.8 | .023 |
| 636 | 647954 | Similar to keratin 8 | LOC647954 | 1.8 | .023 |
| 637 | 25849 | DKFZP564O0823 protein | DKFZP564O0823 | –3 | .023 |
| 638 | 1366 | Claudin 7 | CLDN7 | 1.5 | .023 |
| 639 | 28231 | Solute carrier organic anion transporter family, member 4A1 | SLCO4A1 | 1.6 | .023 |
| 640 | 1437 | Colony stimulating factor 2 (granulocyte-macrophage) | CSF2 | 1.6 | .024 |
| 641 | 375061 | Family with sequence similarity 89, member A | FAM89A | –1.6 | .024 |
| 642 | 5618 | Prolactin receptor | PRLR | –1.7 | .024 |
| 643 | 11081 | Keratocan | KERA | –1.5 | .024 |
| 644 | 55287 | Transmembrane protein 40 | TMEM40 | 1.5 | .024 |
| 645 | 5118 | Procollagen C-endopeptidase enhancer | PCOLCE | –1.9 | .024 |
| 646 | 30061 | Solute carrier family 40 (iron-regulated transporter), member 1 | SLC40A1 | –2.7 | .024 |
| 647 | 115908 | Collagen triple helix repeat containing 1 | CTHRC1 | 1.6 | .024 |
| 648 | 1117 | Chitinase 3-like 2 | CHI3L2 | –1.9 | .024 |
| 649 | 55200 | Pleckstrin homology domain containing, family G (with rhogef domain) member 6 | PLEKHG6 | 1.5 | .024 |
| 650 | 11167 | Follistatin-like 1 | FSTL1 | 1.6 | .024 |
| 651 | 56265 | Carboxypeptidase X (M14 family), member 1 | CPXM1 | –2.7 | .025 |
| 652 | 8511 | Matrix metallopeptidase 23A (pseudogene) | MMP23A | 1.9 | .026 |
| 653 | 7869 | Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B | SEMA3B | –1.5 | .026 |
| 654 | 221476 | Peptidase inhibitor 16 | PI16 | 1.8 | .026 |
| 655 | 7280 | Tubulin, beta 2A | TUBB2A | 1.6 | .026 |
| 656 | 27254 | Cold shock domain containing C2, RNA binding | CSDC2 | –1.5 | .026 |
| 657 | 7128 | Tumor necrosis factor, alpha-induced protein 3 | TNFAIP3 | 1.5 | .026 |
| 658 | 7453 | Tryptophanyl-trna synthetase | WARS | –1.5 | .026 |
| 659 | 56999 | ADAM metallopeptidase with thrombospondin type 1 motif, 9 | ADAMTS9 | –1.6 | .026 |
| 660 | 3885 | Keratin 34 | KRT34 | 2.4 | .026 |
| 661 | 1278 | Collagen, type I, alpha 2 | COL1A2 | 1.9 | .026 |
| 662 | 7123 | C-type lectin domain family 3, member B | CLEC3B | –1.9 | .026 |
| 663 | 7026 | Nuclear receptor subfamily 2, group F, member 2 | NR2F2 | 1.6 | .027 |
| 664 | 10234 | Leucine rich repeat containing 17 | LRRC17 | 2 | .028 |
| 665 | 5029 | Purinergic receptor P2Y, G-protein coupled, 2 | P2RY2 | 1.6 | .028 |
| 666 | 23596 | Opsin 3 | OPN3 | 1.5 | .028 |
| 667 | 6374 | Chemokine (C-X-C motif) ligand 5 | CXCL5 | 2.5 | .028 |
| 668 | 3394 | Interferon regulatory factor 8 | IRF8 | –1.5 | .028 |
| 669 | 64881 | Protocadherin 20 | PCDH20 | –2.2 | .028 |
| 670 | 11326 | V-set and immunoglobulin domain containing 4 | VSIG4 | –1.6 | .029 |
| 671 | 9627 | Synuclein, alpha interacting protein | SNCAIP | –1.9 | .029 |
| 672 | 54922 | Ras interacting protein 1 | RASIP1 | –1.5 | .029 |
| 673 | 3205 | Homeobox A9 | HOXA9 | –1.5 | .029 |
| 674 | 51339 | Dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) | DACT1 | 1.5 | .029 |
| 675 | 6665 | SRY (sex determining region Y)-box 15 | SOX15 | 1.6 | .03 |
| 676 | 54463 | Family with sequence similarity 134, member B | FAM134B | –1.8 | .03 |
| 677 | 6035 | Ribonuclease, rnase A family, 1 (pancreatic) | RNASE1 | –1.5 | .03 |
| 678 | 3983 | Actin binding LIM protein 1 | ABLIM1 | –1.7 | .031 |
| 679 | 25975 | EGF-like-domain, multiple 6 | EGFL6 | 2.4 | .031 |
| 680 | 7364 | UDP glucuronosyltransferase 2 family, polypeptide B7 | UGT2B7 | –1.5 | .031 |
| 681 | 647169 | Similar to glutathione transferase | LOC647169 | –2.3 | .031 |
| 682 | 1902 | Lysophosphatidic acid receptor 1 | LPAR1 | –1.7 | .031 |
| 683 | 10267 | Receptor (G protein-coupled) activity modifying protein 1 | RAMP1 | –2.2 | .032 |
| 684 | 3691 | Integrin, beta 4 | ITGB4 | 1.5 | .032 |
| 685 | 10235 | RAS guanyl releasing protein 2 (calcium and DAG-regulated) | RASGRP2 | –1.7 | .032 |
| 686 | 2266 | Fibrinogen gamma chain | FGG | –2.8 | .032 |
| 687 | 647954 | Similar to keratin 8 | LOC647954 | 1.6 | .033 |
| 688 | 85352 | Kiaa1644 | KIAA1644 | –1.7 | .033 |
| 689 | 10135 | Nicotinamide phosphoribosyltransferase | NAMPT | 1.6 | .033 |
| 690 | 972 | CD74 molecule, major histocompatibility complex, class II invariant chain | CD74 | –1.6 | .033 |
| 691 | 152816 | Chromosome 4 open reading frame 26 | C4orf26 | 2.2 | .033 |
| 692 | 3122 | Major histocompatibility complex, class II, DR alpha | HLA-DRA | –1.7 | .033 |
| 693 | 115908 | Collagen triple helix repeat containing 1 | CTHRC1 | 1.6 | .034 |
| 694 | 3732 | CD82 molecule | CD82 | –1.6 | .034 |
| 695 | 5092 | Pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha | PCBD1 | –1.5 | .034 |
| 696 | 2719 | Glypican 3 | GPC3 | 1.5 | .034 |
| 697 | 4316 | Matrix metallopeptidase 7 (matrilysin, uterine) | MMP7 | –2 | .034 |
| 698 | 375061 | Family with sequence similarity 89, member A | FAM89A | –1.5 | .034 |
| 699 | 8532 | Carboxypeptidase Z | CPZ | –1.5 | .035 |
| 700 | 9241 | Noggin | NOG | 1.6 | .035 |
| 701 | 1291 | Collagen, type VI, alpha 1 | COL6A1 | 1.5 | .035 |
| 702 | 760 | Carbonic anhydrase II | CA2 | 1.7 | .036 |
| 703 | 3134 | Major histocompatibility complex, class I, F | HLA-F | –1.6 | .036 |
| 704 | 25975 | EGF-like domain, multiple 6 | EGFL6 | 1.8 | .036 |
| 705 | 8839 | WNT1 inducible signaling pathway protein 2 | WISP2 | 1.6 | .037 |
| 706 | 164781 | WD repeat domain 69 | WDR69 | 1.5 | .038 |
| 707 | 128346 | Chromosome 1 open reading frame 162 | C1orf162 | –1.5 | .038 |
| 708 | 3852 | Keratin 5 | KRT5 | 2.6 | .039 |
| 709 | 10135 | Nicotinamide phosphoribosyltransferase | NAMPT | 1.7 | .039 |
| 710 | 23596 | Opsin 3 | OPN3 | 1.5 | .039 |
| 711 | 7857 | Secretogranin II (chromogranin C) | SCG2 | 1.5 | .04 |
| 712 | 84171 | Lysyl oxidase-like 4 | LOXL4 | 1.7 | .04 |
| 713 | 3976 | Leukemia inhibitory factor (cholinergic differentiation factor) | LIF | 1.7 | .04 |
| 714 | 2938 | Glutathione S-transferase alpha 1 | GSTA1 | –2.5 | .04 |
| 715 | 5930 | Retinoblastoma binding protein 6 | RBBP6 | –1.6 | .041 |
| 716 | 4257 | Microsomal glutathione S-transferase 1 | MGST1 | –1.7 | .041 |
| 717 | 725 | Complement component 4 binding protein, beta | C4BPB | 1.5 | .041 |
| 718 | 5972 | Renin | REN | –1.6 | .042 |
| 719 | 3601 | Interleukin 15 receptor, alpha | IL15RA | –1.6 | .042 |
| 720 | 23650 | Tripartite motif-containing 29 | TRIM29 | 1.8 | .042 |
| 721 | 25789 | Transmembrane protein 59-like | TMEM59L | –1.8 | .042 |
| 722 | 375061 | Family with sequence similarity 89, member A | FAM89A | –1.6 | .043 |
| 723 | 94121 | Synaptotagmin-like 4 | SYTL4 | –1.6 | .044 |
| 724 | 79191 | Iroquois homeobox 3 | IRX3 | –1.7 | .044 |
| 725 | 23286 | WW and C2 domain containing 1 | WWC1 | 1.6 | .044 |
| 726 | 3128 | Major histocompatibility complex, class II, DR beta 6 (pseudogene) | HLA-DRB6 | –1.7 | .045 |
| 727 | 8854 | Aldehyde dehydrogenase 1 family, member A2 | ALDH1A2 | –3.2 | .045 |
| 728 | 1382 | Cellular retinoic acid binding protein 2 | CRABP2 | 1.8 | .045 |
| 729 | 4239 | Microfibrillar-associated protein 4 | MFAP4 | –2.3 | .046 |
| 730 | 5155 | Platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) | PDGFB | 1.5 | .046 |
| 731 | 9332 | CD163 molecule | CD163 | –1.7 | .047 |
| 732 | 6035 | Ribonuclease, rnase A family, 1 (pancreatic) | RNASE1 | –1.6 | .047 |
| 733 | 4316 | Matrix metallopeptidase 7 (matrilysin, uterine) | MMP7 | –1.8 | .047 |
| 734 | 760 | Carbonic anhydrase II | CA2 | 1.9 | .047 |
| 735 | 2702 | Gap junction protein, alpha 5, 40 kd | GJA5 | 1.6 | .048 |
| 736 | 3983 | Actin binding LIM protein 1 | ABLIM1 | –1.5 | .048 |
| 737 | 9332 | CD163 molecule | CD163 | –1.5 | .048 |
| 738 | 57124 | CD248 molecule, endosialin | CD248 | –2.2 | .048 |
| 739 | 6907 | Transducin (beta)-like 1X-linked | TBL1X | –1.6 | .049 |
| 740 | 2317 | Filamin B, beta (actin binding protein 278) | FLNB | 1.5 | .049 |
| 741 | 1577 | Cytochrome P450, family 3, subfamily A, polypeptide 5 | CYP3A5 | –1.8 | .049 |
| 742 | 6947 | Transcobalamin I (vitamin B12 binding protein, R binder family) | TCN1 | 2 | .049 |
| 743 | 22943 | Dickkopf homolog 1 (Xenopus laevis) | DKK1 | –2.2 | .049 |
| 744 | 3667 | Insulin receptor substrate 1 | IRS1 | –1.5 | .05 |
| 745 | 64220 | Stimulated by retinoic acid gene 6 homolog (mouse) | STRA6 | –1.6 | .05 |
| 746 | 3691 | Integrin, beta 4 | ITGB4 | 1.6 | .052 |
| 747 | 121506 | Endoplasmic reticulum protein 27 | ERP27 | 1.5 | .052 |
| 748 | 347 | Apolipoprotein D | APOD | –3.6 | .052 |
| 749 | 8532 | Carboxypeptidase Z | CPZ | –1.7 | .052 |
| 750 | 27345 | Potassium large conductance calcium-activated channel, subfamily M, beta member 4 | KCNMB4 | 1.5 | .053 |
| 751 | 5266 | Peptidase inhibitor 3, skin-derived | PI3 | 2.6 | .053 |
| 752 | 2812 | Glycoprotein Ib (platelet), beta polypeptide | GP1BB | –1.9 | .053 |
| 753 | 83481 | Epiplakin 1 | EPPK1 | 1.8 | .053 |
| 754 | 200150 | Phospholipase D family, member 5 | PLD5 | 1.5 | .054 |
| 755 | 3856 | Keratin 8 | KRT8 | 1.6 | .054 |
| 756 | 23037 | PDZ domain containing 2 | PDZD2 | –1.5 | .055 |
| 757 | 5317 | Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) | PKP1 | 1.8 | .056 |
| 758 | 3122 | Major histocompatibility complex, class II, DR alpha | HLA-DRA | –1.7 | .058 |
| 759 | 9469 | Carbohydrate (chondroitin 6) sulfotransferase 3 | CHST3 | –1.6 | .059 |
| 760 | 27122 | Dickkopf homolog 3 (Xenopus laevis) | DKK3 | 1.7 | .059 |
| 761 | 27122 | Dickkopf homolog 3 (Xenopus laevis) | DKK3 | 1.8 | .059 |
| 762 | 8710 | Serpin peptidase inhibitor, clade B (ovalbumin), member 7 | SERPINB7 | 2.3 | .06 |
| 763 | 1009 | Cadherin 11, type 2, OB-cadherin (osteoblast) | CDH11 | –1.7 | .061 |
| 764 | 1999 | E74-like factor 3 (ets domain transcription factor, epithelial-specific) | ELF3 | 1.5 | .061 |
| 765 | 83988 | Neurocalcin delta | NCALD | –1.5 | .062 |
| 766 | 6374 | Chemokine (C-X-C motif) ligand 5 | CXCL5 | 2.1 | .062 |
| 767 | 50801 | Potassium channel, subfamily K, member 4 | KCNK4 | –1.7 | .063 |
| 768 | 5866 | RAB3A interacting protein (rabin3)-like 1 | RAB3IL1 | –1.6 | .064 |
| 769 | 1066 | Carboxylesterase 1 (monocyte/macrophage serine esterase 1) | CES1 | –1.7 | .065 |
| 770 | 2938 | Glutathione S-transferase alpha 1 | GSTA1 | –1.9 | .067 |
| 771 | 1440 | Colony stimulating factor 3 (granulocyte) | CSF3 | 1.6 | .067 |
| 772 | 3429 | Interferon, alpha-inducible protein 27 | IFI27 | –1.6 | .067 |
| 773 | 1440 | Colony stimulating factor 3 (granulocyte) | CSF3 | 1.8 | .068 |
| 774 | 23650 | Tripartite motif-containing 29 | TRIM29 | 1.5 | .069 |
| 775 | 6349 | Chemokine (C-C motif) ligand 3-like 1 | CCL3L1 | 2.4 | .069 |
| 776 | 2125 | Envoplakin | EVPL | 2 | .069 |
| 777 | 23428 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 | SLC7A8 | –1.6 | .07 |
| 778 | 644743 | Similar to NCK-associated protein 1 | LOC644743 | 1.6 | .07 |
| 779 | 2273 | Four and one half LIM domains 1 | FHL1 | –1.6 | .07 |
| 780 | 85409 | Naked cuticle homolog 2 ( Drosophila ) | NKD2 | –1.9 | .071 |
| 781 | 8511 | Matrix metallopeptidase 23A (pseudogene) | MMP23A | 1.5 | .071 |
| 782 | 216 | Aldehyde dehydrogenase 1 family, member A1 | ALDH1A1 | –1.9 | .072 |
| 783 | 84432 | Prokineticin 1 | PROK1 | –1.9 | .072 |
| 784 | 152 | Adrenergic, alpha-2C-, receptor | ADRA2C | –1.7 | .072 |
| 785 | 10234 | Leucine rich repeat containing 17 | LRRC17 | 1.7 | .073 |
| 786 | 7472 | Wingless-type MMTV integration site family member 2 | WNT2 | 1.6 | .074 |
| 787 | 3487 | Insulin-like growth factor binding protein 4 | IGFBP4 | –1.5 | .074 |
| 788 | 10365 | Kruppel-like factor 2 (lung) | KLF2 | –1.5 | .075 |
| 789 | 1462 | Versican | VCAN | –1.6 | .075 |
| 790 | 8406 | Sushi-repeat-containing protein, X-linked | SRPX | –1.8 | .075 |
| 791 | 150696 | Prominin 2 | PROM2 | 1.7 | .076 |
| 792 | 392371 | Keratin 18 pseudogene 13 | KRT18P13 | 1.6 | .076 |
| 793 | 84419 | Chromosome 15 open reading frame 48 | C15orf48 | 1.8 | .077 |
| 794 | 79026 | AHNAK nucleoprotein | AHNAK | 1.6 | .077 |
| 795 | 10457 | Glycoprotein (transmembrane) nmb | GPNMB | –1.5 | .079 |
| 796 | 165 | AE binding protein 1 | AEBP1 | –1.6 | .079 |
| 797 | 26577 | Procollagen C-endopeptidase enhancer 2 | PCOLCE2 | –1.7 | .08 |
| 798 | 9249 | Dehydrogenase/reductase (SDR family) member 3 | DHRS3 | –1.8 | .083 |
| 799 | 6349 | Chemokine (C-C motif) ligand 3-like 1 | CCL3L1 | 2.1 | .083 |
| 800 | 2939 | Glutathione S-transferase alpha 2 | GSTA2 | –1.9 | .085 |
| 801 | 5159 | Platelet-derived growth factor receptor, beta polypeptide | PDGFRB | –1.7 | .085 |
| 802 | 5329 | Plasminogen activator, urokinase receptor | PLAUR | 1.5 | .085 |
| 803 | 9332 | CD163 molecule | CD163 | –1.6 | .086 |
| 804 | 126393 | Heat shock protein, alpha-crystallin-related, B6 | HSPB6 | –2.1 | .087 |
| 805 | 81706 | Protein phosphatase 1, regulatory (inhibitor) subunit 14C | PPP1R14C | 1.9 | .088 |
| 806 | 9315 | Chromosome 5 open reading frame 13 | C5orf13 | 1.5 | .089 |
| 807 | 7805 | Lysosomal multispanning membrane protein 5 | LAPTM5 | –1.6 | .09 |
| 808 | 84419 | Chromosome 15 open reading frame 48 | C15orf48 | 1.9 | .091 |
| 809 | 3671 | Immunoglobulin superfamily containing leucine-rich repeat | ISLR | –2.2 | .091 |
| 810 | 9935 | V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) | MAFB | –1.5 | .093 |
| 811 | 387882 | Chromosome 12 open reading frame 75 | C12orf75 | 1.5 | .093 |
| 812 | 6920 | Transcription elongation factor A (SII), 3 | TCEA3 | 1.5 | .094 |
| 813 | 80781 | Collagen, type XVIII, alpha 1 | COL18A1 | –1.6 | .094 |
| 814 | 7941 | Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) | PLA2G7 | –1.7 | .096 |
| 815 | 216 | Aldehyde dehydrogenase 1 family, member A1 | ALDH1A1 | –1.9 | .1 |
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
